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1. Abstract 
 
Charcot-Marie-Tooth (CMT) type 1 neuropathies are a genetically heterogeneous group of 
non-treatable inherited disorders affecting the peripheral nervous system that lead to 
sensory and motor dysfunction. Secondary low grade inflammation, implicating the innate 
and adaptive immune system, could previously be identified as a substantial disease 
modifier in two mouse models for CMT1, CMT1B and 1X, respectively. However, the 
exact mechanism how the adaptive immune system contributes to disease pathogenesis is 
not completely understood. Based on observations that the accumulation of endogenous 
antibodies to myelin components is important for rapid myelin clearance after nerve injury 
during Wallerian degeneration, a possibly similar mechanism was considered for 
endogenous antibodies as disease amplifier in mice heterozygously deficient for P0 
(P0het), mimicking some typical features of CMT1B.  
 
In this study an increased antibody deposition was detected in the affected peripheral 
nerves of P0het myelin mutant mice. By crossbreeding P0het mutants with mice 
specifically lacking B-lymphocytes, and therefore antibodies (JHD-/-), a decline of 
endoneurial macrophages together with a substantially ameliorated demyelination could be 
demonstrated in 6-month-old mutant mice. Moreover, reconstitution with murine IgGs 
reverted the neuropathic phenotype, substantiating that endogenous antibodies are 
potentially pathogenic at this early stage of disease. Unexpectedly, in 12-months-old P0het 
mutants, JHD deficiency resulted in disease aggravation accompanied by an increased 
inflammatory reaction and M2-polarized macrophage response.  
 
These observations suggest that in a mouse model for CMT1B, the lack of endogenous 
antibodies has a dichotomous effect: ameliorating early macrophage-mediated 
demyelination, as opposed to increasing inflammatory reactions leading to disease 
aggravation at older ages. 
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2. Zusammenfassung 
 
Als Charcot-Marie-Tooth (CMT) Typ 1 Erkrankungen bezeichnet man eine genetisch 
heterogene Gruppe von nicht behandelbaren, erblichen Neuropathien, die das periphere 
Nervensystem betreffen und letztendlich zu starken motorischen und sensorischen 
Defiziten führen. Anhand verschiedener Studien konnte gezeigt werden, dass sekundäre 
Entzündungsreaktionen, insbesondere des angeborenen und adaptiven Immunsystems, eine 
entscheidende Rolle bei der Pathogenese von zwei verschiedenen CMT1-Mausmodellen 
(CMT1B und CMT1X) spielen. Jedoch ist der genaue Mechanismus, in dem das adaptive 
Immunsystem zur Pathogenese beiträgt, nicht komplett bekannt. In einer veröffentlichten 
Studie wurden gebundenen endogenen Antiköpern eine wichtige Rolle beim raschen 
Myelinabbau nach Nervläsion während der Waller´schen Degeneration zugeschrieben. In 
Mäusen, die heterozygot defizient für P0 (P0het) sind und einige typische Merkmale der 
CMT1B Neuropathie aufweisen, sollte ein möglicherweise ähnlicher Mechanismus von 
endogenen Antikörpern untersucht werden, der zur Verstärkung der 
Krankheitsentwicklung führt. 
 
In dieser Studie konnte eine vermehrte Antikörperbindung in den betroffenen peripheren 
Nerven von P0het Myelinmutanten beobachtet werden. Anhand von Verkreuzungs-
Experimenten von P0het Mutanten mit Mäusen, die keine B-Lymphozyten besitzen und 
daher keine Antikörper bilden können (JHD-/-), konnte zudem in den untersuchten 6 
Monate alten Doppelmutanten eine verringerte Anzahl endoneuraler Makrophagen und 
eine deutliche Verbesserung der Demyelinisierung aufgezeigt werden. Zusätzlich konnte 
anhand von Rekonstitutions-Experimenten mit mausspezifischen-IgGs der neuropathische 
Phänotyp in peripheren Nerven wiederhergestellt werden, was die mögliche 
pathogenetische Rolle endogener Antikörper im frühen Stadium der Erkrankung bekräftigt. 
Unerwarteterweise führte die JHD-Defizienz jedoch in 12 Monate alten P0het 
Mausmutanten eher zu einer Verschlechterung der Neuropathie, zusammen mit einer 
verstärkten Entzündungsreaktion und M2-polarisierten Makrophagen-Aktivierung.  
 
Diese Beobachtungen deuten darauf hin, dass das Fehlen von Antikörpern in einem 
etablierten Mausmodell für CMT1B unterschiedliche Folgen hat, da dies zu einer 
verringerten Makrophagen-vermittelten Demyelinisierung im frühen Erkrankungsverlauf 
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führt, gleichzeitig aber im späteren Alter in einer verstärkten Entzündungsreaktion und 
einem vermehrten Nervschaden resultiert. 
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3. Introduction 
 
3.1. Charcot-Marie-Tooth neuropathies 
 
Charcot-Marie-Tooth (CMT) disease, also known as hereditary motor and sensory 
neuropathy (HMSN), is a genetically heterogeneous group of non-treatable hereditary 
neuropathies with a prevalence of 1:2500 affecting the peripheral nervous system (PNS). 
They are named after Jean-Martin Charcot, Pierre Marie, and Howard Tooth, who first 
described the disease in 1886. CMT is divided into demyelinating (CMT1 and CMT4) and 
axonal neuropathies (CMT2), whereas severely affected patients diagnosed with congenital 
hypomyelinating neuropathies (CHN) or Dejerine-Sottas neuropathies (DSN) are 
designated as CMT3 (Reilly and Shy, 2009; Patzko and Shy, 2011). Usually nerve 
conduction velocity (NCV) measurements are used as a diagnostic tool to distinguish 
between demyelinating (<38 m/s) or axonal forms (>38 m/s) (Reilly and Shy, 2009; Patzko 
and Shy, 2011). The age of onset can vary from early childhood to adulthood. Patients are 
clinically characterized by progressive distal muscle weakness, muscle wasting, sensory 
dysfunction, skeletal abnormalities (scoliosis) and food deformities (pes cavus), as well as 
the classical ‘steppage’ gait (Saporta and Shy, 2013; Brennan et al., 2015). To date no 
causative cure is available and only rehabilitative strategies or surgeries are available as 
therapeutic approaches for CMT patients (Schenone et al., 2011).  
 
In the last years new diagnostic tools (high-throughput sequencing) in research made it 
possible to discover underlying genetic causes and new mutations in CMT. So far, 
mutations in over 80 disease-causing genes have been described (Timmerman et al., 2014) 
and the most common forms are described below. A 1.4-Mb duplication on chromosome 
17, containing the peripheral myelin protein 22 (PMP22) gene, is responsible for the most 
frequent form of CMT, CMT1A (Reilly et al., 2011). The X-chromosomal dominant form 
of CMT, CMT1X, is the second most common subtype and caused by mutations in the 
gene encoding the gap junction protein Connexin 32 (Cx32/Gjb1). More than 300 
causative mutations have been described in this gene (Kleopa and Scherer, 2006; Reilly et 
al., 2011). CMT1 type B comprises about 5-10% of all CMT1 patients and is caused by 
mutations in myelin protein zero (MPZ/P0). Some mutations in the MPZ/P0 gene are also 
associated with the severe early onset neuropathy CMT3 (Shy et al., 2004). Thirteen genes 
have been identified to cause the autosomal recessive form of CMT, CMT4. Among these 
are mutations in myotubularin-related protein (MTMR2), periaxin or EGR2, also known as 
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KROX20 (Reilly et al., 2011; Brennan et al., 2015). Most of these cause a demyelinating 
neuropathy. The axonal subtype CMT2 can result - among others - from mutations in 
mitofusin 2 (MFN2) or the neurofilament light polypeptide gene (NEFL). They can affect 
mitochondrial function and energy support, neurofilament assembly, as well as axonal 
transport (Shy and Patzko, 2011; Jerath and Shy, 2015). 
 
 
3.2. Rodent models for CMT1 
 
In the past years a series of genetically modified rodent models have been generated in 
CMT1 research (Fledrich et al., 2012). Similar to patient biopsies, peripheral nerves of 
mouse models show typical hallmarks such as segmental demyelination, axonal 
degeneration, and formation of ‘onion bulbs’. The latter are supernumerary Schwann cells 
(SCs) that share the expression of molecules typical for immature SCs (Guenard et al., 
1996; Klein et al., 2014) and possibly develop from consecutive episodes of de- and 
remyelination (Suter and Scherer, 2003; Casasnovas et al., 2008). 
 
In mouse models for CMT1A it was demonstrated that the degree of nerve fiber damage 
correlates with the level of PMP22 expression. For instance, PMP22 overexpressing mice 
with seven copies of the human gene (strain C22) develop an obvious neuropathic 
phenotype with pronounced demyelination. In contrast, heterozygous C61 mice with only 
four copies of PMP22 are characterized by a milder neuropathic phenotype (Huxley et al., 
1996; Huxley et al., 1998). Moreover, homozygous transgenic rats with three extra copies 
of the murine PMP22 gene develop a severe phenotype, whereas heterozygous rats are less 
affected and characterized by motor impairment and demyelination, resembling human 
CMT1A patients (Sereda et al., 1996). 
 
Although more than 300 mutations have been described for the X-linked form of CMT1, 
most of them result in a rather uniform clinical phenotype. Therefore, CMT1X is 
considered to be caused by loss of function mutations (Kleopa and Scherer, 2006; Reilly et 
al., 2011). Corresponding mice with deleted Cx32/Gjb1 alleles (Cx32def) develop a 
progressive, demyelinating peripheral neuropathy beginning at approximately 3 months of 
age comparable to those abnormalities associated with human CMT1X (Anzini et al., 
1997; Scherer et al., 1998). 
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To date, more than 100 different mutations in the MPZ/P0 gene are known which result in 
a variable outcome (Gabreels-Festen et al., 1996). Several point mutations and deletions 
are associated with human CMT1B (Hayasaka et al., 1993c; Hayasaka et al., 1993b; 
Hayasaka et al., 1993a; Himoro et al., 1993; Kulkens et al., 1993; Nelis et al., 1994). 
Among these mutations, a deletion of serine 63 was identified to cause CMT1B (Kulkens 
et al., 1993) and the corresponding MpzS63del model exhibits demyelination and reduced 
NCV. Moreover, it was shown that the mutated protein is retained in the endoplasmic 
reticulum and activates the unfolded protein response (UPR) (Wrabetz et al., 2006). On the 
other hand heterozygous knockout mice (P0het) that were used in this study, show mainly 
normal myelin until postnatal week 10, but develop a mild, progressive neuropathy and are 
characterized by demyelination, formation of onion bulbs and a reduced motor NCV 
(Giese et al., 1992; Martini et al., 1995; Shy et al., 1997). Of note, mainly motor axons are 
affected in most of the described animal models, which is in contrast to affected human 
sensory sural nerve biopsies (Martini, 1997). 
 
It has been reported that P0het, Cx32def, and PMP22tg (C61) mice develop characteristic 
molecular abnormalities (Klein et al., 2014). However, despite the different nature and 
function of mutated proteins, corresponding mouse models develop a similar disease 
outcome. These similarities in the nerve phenotype might suggest the activation of 
common pathomechanisms that will be described in the following part. 
 
 
3.3. Low grade inflammation as an important amplifier in the pathogenesis of CMT1 
 
3.3.1. The innate immune system 
 
Several previous studies could demonstrate that chronic low grade inflammation acts as a 
substantial disease modifier in the pathogenesis of distinct CMT1 mouse models (Martini 
et al., 2008; Martini et al., 2013). An age-dependent increase in the number of endoneurial 
macrophages - as a part of the innate immune system - has been described in peripheral 
nerves of mutant mice compared to wildtype littermates (Schmid et al., 2000; Carenini et 
al., 2001; Kobsar et al., 2002; Kobsar et al., 2005). Moreover, macrophages in myelin 
mutant mice enter endoneurial tubes and often acquire a ‘foamy’ appearance due to 
increased myelin phagocytosis and subsequent degradation (Ip et al., 2006). Interestingly, 
the dynamic in the increase of macrophages numbers differs between distinct CMT1 
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mouse models. P0het and Cx32def myelin mutant mice are characterized by gradually 
increasing macrophage numbers beginning at 3 months of age (Schmid et al., 2000; 
Carenini et al., 2001; Kobsar et al., 2002), whereas PMP22tg mice show an initial 
elevation of macrophage numbers that only moderately increase during aging (Kobsar et 
al., 2005; Kohl et al., 2010a). This correlates also with the course of the disease, as 
PMP22tg mice exhibit already early signs of pathological alterations compared to the other 
two models (Klein et al., 2014).  
 
To date, at least two important mediators of macrophage activation have been identified in 
mouse models for CMT1. These are the Schwann cell derived chemokine CCL2 (also 
known as MCP-1: monocyte chemoattractant protein-1) and the fibroblast derived colony 
stimulating factor-1 (CSF-1/M-CSF) (Groh et al., 2010; Groh et al., 2012). It could be 
shown that the expression of both cytokines is elevated in peripheral nerves of myelin 
mutant mice compared to wildtype littermates (Fischer et al., 2008b; Groh et al., 2010; 
Groh et al., 2012). CSF-1 is the pivotal regulator of macrophage function and survival 
(Chitu and Stanley, 2006) and it was shown that CSF-1 stimulates the proliferation of 
nerve-resident macrophages (Müller et al., 2007). Moreover, crossbreeding experiments 
with osteopetrotic (op) mice that have an inactivating mutation in the coding region of 
CSF-1 (Yoshida et al., 1990) demonstrated for the first time that macrophages actively 
contribute to the pathological alterations seen in CMT1 mutant mice (Carenini et al., 2001; 
Groh et al., 2012). In P0het and Cx32def mice, the lack of CSF-1 prevented the increase in 
macrophage numbers in peripheral nerves and led to a robust and persistent amelioration of 
the demyelinating phenotype, preservation of axons, and reduced muscle denervation 
(Carenini et al., 2001; Groh et al., 2012; Groh et al., 2015). Similar consequences of CSF-1 
deficiency were observed in PMP22tg mutant mice (Groh and Martini, unpublished 
observations). In contrast, bone marrow transplantation studies in the corresponding CMT1 
mouse models revealed that CCL2 is important for the infiltration of macrophages into 
peripheral nerves in P0het and Cx32def mice (Fischer et al., 2008b; Groh et al., 2010) and 
crossbreeding experiments with CCL2-deficient mice gave further evidence for a 
functional role of macrophages in the pathogenesis of CMT1 mouse models. P0het, 
Cx32def, and PMP22tg mice that were heterozygously deficient for CCL2 - and therefore 
expressed only half the dose of the chemokine - showed substantially attenuated 
macrophage recruitment and an ameliorated demyelinating phenotype. Moreover, axonal 
properties were significantly improved in the CMT1X mouse model (Groh et al., 2010). 
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Interestingly, the complete absence of CCL2 did not attenuate macrophage numbers and 
ameliorate the demyelinating phenotype in peripheral nerves of P0het and Cx32def mice. 
A likely compensatory upregulation of CSF-1 expression and subsequent proliferation of 
nerve-resident macrophages counteracts the reduced infiltration of macrophages from the 
periphery, revealing a correlation between the total number of endoneurial macrophages 
and subsequent nerve damage (Fischer et al., 2008b; Groh et al., 2010). Additionally, by 
crossbreeding P0het mutants with mice lacking the macrophage-restricted adhesion 
molecule sialoadhesin (Siglec-1) (Oetke et al., 2006), the corresponding double mutants 
had reduced numbers of endoneurial macrophages together with an ameliorated 
demyelinating phenotype (Kobsar et al., 2006). 
 
Together these results demonstrate that macrophages are actively involved in disease 
development, however, the exact mechanisms that contribute to macrophage-mediated 
demyelination and axonal perturbation in CMT1 mouse models need to be further 
investigated. 
 
3.3.2. The adaptive immune system 
 
Other studies showed that - in addition to the innate immune system - the adaptive immune 
system is involved in the pathogenesis of CMT1 mouse models. First evidence for a 
contribution of the adaptive immune system was gained by observations that some patients 
responded positively upon immunomodulation (Dyck et al., 1982). Moreover, lymphocytes 
were elevated in the blood of CMT patients (Williams et al., 1987; Williams et al., 1993) 
and peripheral nerves of myelin mutant mice (Shy et al., 1997; Schmid et al., 2000). A 
detrimental role of the adaptive immune system could be demonstrated, when RAG1-
deficient mice that lack both mature T- and B-lymphocytes (Mombaerts et al., 1992) were 
crossbred with P0het and Cx32def mice. This caused a persistent and substantial 
amelioration of demyelination and axonal perturbation together with a reduction of 
macrophages (Schmid et al., 2000; Kobsar et al., 2003). However, no beneficial effect was 
detectable in PMP22tg mutant mice that were RAG1-deficient (Kohl et al., 2010b). Further 
crossbreeding experiments of P0het mutant mice with TCR-α-deficient mice (Philpott et 
al., 1992), lacking αβ T-lymphocytes, but with normal B-lymphocytes, resulted also in an 
amelioration of the demyelinating phenotype (Schmid et al., 2000). In a reciprocal 
experiment, P0het mice deficient for the co-inhibitory molecule programmed cell death-1 
(PD-1), which is expressed on the surface of activated T- and B-lymphocytes, showed an 
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increased inflammatory reaction and aggravated neuropathy, corroborating the impact of 
the adaptive immune system (Kroner et al., 2009). Furthermore, transplantation of 
wildtype bone marrow into RAG1-deficient P0het mice reverted the beneficial effect of 
RAG1 deficiency, confirming the direct pathogenic role of lymphocytes (Mäurer et al., 
2001). Based on these results and the observations that T-lymphocytes, but not B-
lymphocytes, are present in peripheral nerves and increase in numbers during disease 
progression, CD8-positive T-lymphocytes were considered to be the culprit cells 
contributing to the pathogenic process (Schmid et al., 2000; Mäurer et al., 2001). However, 
by means of further bone marrow reconstitution experiments into P0het RAG1-/- mice, 
neither CD8- nor CD4-positive T-lymphocytes could be unequivocally identified as the 
only pathogenic mediators (Kroner and Martini, unpublished observations).  
 
The search for an alternative explanation for these latter observations and for the beneficial 
effect of RAG1 deficiency in myelin mutants shifted the focus on B-lymphocytes. They 
can give rise either to antigen-presenting cells or to plasma cells, the main source for 
antibody production (Mauri and Bosma, 2012). Favoring the possibility of antibodies, a 
recent study could reveal an important role of immunoglobulins following peripheral nerve 
injury during Wallerian degeneration (Vargas et al., 2010). The authors detected that 
endogenous antibodies rapidly accumulate after crush injury along myelinated fibers distal 
to the lesion site and contribute to the recruitment of macrophages. Furthermore, they 
demonstrated that mice deficient for B-lymphocytes, and therefore lacking antibodies, 
exert a reduced macrophage activation leading to delayed removal of myelin debris and 
compromised regeneration after nerve injury (Vargas et al., 2010).  
 
In the present study the hypothesis was tested whether endogenous antibodies could 
function as potential recognition signals for phagocytosing macrophages in peripheral 
nerves of a CMT1B mouse model (P0het) and thereby contribute to disease pathogenesis. 
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3.4. Aim of the study 
 
Immune reactions, implicating the innate and adaptive immune system, are functionally 
important modulators in mouse models for CMT1, representing non-treatable, inherited 
disorders affecting the peripheral nervous system. However, the exact mechanism how the 
adaptive immune system contributes to disease pathogenesis is not completely understood.  
Since antibodies have recently been shown to contribute to myelin clearance during 
Wallerian degeneration, the aim of this study was to analyze the impact of endogenous 
antibodies in a mouse model for CMT1B (P0het) by addressing the following issues: 
 
- Investigating if antibodies are deposited in peripheral nerves of myelin mutant mice. 
 
- Studying the pathological relevance of antibody depositions:  
 
 - by investigating macrophage activation and nerve pathology when antibodies are 
genetically depleted in P0het mice. 
 
 - by scoring the effect of antibody reconstitution in genetically depleted P0het 
mice. 
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4. Material and methods   
 
4.1. Equipment, buffers and solutions, antibodies, and primer sequences 
 
Technical equipment (Appendix 8.1), reagents (Appendix 8.2), buffers and solutions 
(Appendix 8.3) as well as primer sequences for genotyping (Appendix 8.4) and antibodies 
for immunohistochemistry (Appendix 8.5) are listed in detail in the appendices. Unless 
mentioned otherwise, standard material was used for laboratory work. 
 
4.2 Animals and genotyping 
 
Mice heterozygously deficient for P0 (P0het) (Giese et al., 1992) were crossbred with 
animals specifically lacking B-lymphocytes (JHD-/-) (Chen et al., 1993) according to 
previously published protocols (Schmid et al., 2000) and investigated at 6 and 12 months 
of age with the corresponding littermates of both gender. Additionally, RAG1-deficient 
mice, lacking both B- and T-lymphocytes, were analyzed (Mombaerts et al., 1992). All 
mice were on a C57BL/6N background and genotypes were identified after purification of 
genomic DNA from ear biopsies using DNeasy blood & tissue kit (Qiagen) according to 
the manufacturer’s guidelines. Genotypes were determined by conventional PCR 
(respective primer sequences listed in appendix 8.4). Animals were kept in the animal 
facility of the Department of Neurology, University clinic of Wuerzburg, in a 12h/12h day 
(<300 lux)/night rhythm under barrier conditions using individually ventilated cages. All 
animal experiments were approved by the local authority, the Government of Lower 
Franconia, Germany. 
 
4.3. Sciatic nerve crush injury 
 
Wildtype mice were deeply anesthetized by an intraperitoneal injection of a mixture of 
ketavet and xylavet (10 μl per g body weight). The right sciatic nerve was exposed and 
crushed at the region of the sciatic notch by using a non-serrated clamp with a constant 
pressure for 15 s. This resulted in a completely translucent appearance of the crushed area 
of the nerve. After 3 days, the mice were sacrificed and lesioned nerves were removed for 
analysis of complement deposition (see below). All operations were performed by Dr. Chi 
Wang Ip. 
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4.4 Dissection and tissue processing  
 
For preparation of fresh frozen spleens, flexor digitorum brevis muscles and femoral 
nerves, animals were killed by asphyxiation with CO2 (according to guidelines by the State 
Office of Health and Social Affairs Berlin), blood was transcardially rinsed with 
phosphate-buffered saline (PBS) containing heparin, followed by harvesting and 
embedding nerves in O.C.T. medium and frozen in liquid nitrogen-cooled methyl butane. 
For isolation of total RNA and protein, tissue was snap frozen in liquid nitrogen and stored 
at -80°C. 
 
In case of preparation for fixed femoral nerves, blood was transcardially rinsed with 
PBS/heparin and a perfusion with 4% paraformaldehyde (PFA) in PBS for 10 min was 
performed. Dissected nerves were post-fixed in the same solution for 2 h, stored in 30% 
sucrose/PBS over night at 4°C, and embedded in O.C.T. medium. Fresh frozen and fixed 
peripheral nerves were cut into 10 µm-thick cross-sections on a cryostat (Leica) and stored 
at -20°C before further processing. 
 
For single teased fiber preparations, blood was transcardially rinsed with PBS/heparin 
followed by perfusion with 2% PFA in PBS for 10 min. Femoral quadriceps and sciatic 
nerves were dissected, the perineurium removed and single fibers were separated by 
forceps on glass slides. Alternatively, blood was transcardially rinsed with PBS/heparin 
and unfixed sciatic nerves were separated into small fiber bundles followed by incubation 
in PBS in a 96-well plate (free floating). 
 
For electron microscopy, mice were transcardially rinsed with PBS/heparin followed by 
perfusion with 4% PFA and 2% glutaraldehyde in 0.1M cacodylate buffer for 15 min. 
Dissected nerves were post-fixed in the same solution over night at 4°C. After osmification 
with 2% osmiumtetroxide in 0.1M cacodylate buffer (2 h) and dehydration in ascending 
acetone concentrations samples were embedded in Spurr’s medium. Semithin sections (0.5 
μm) were stained with alkaline methylene blue and analyzed by light microscopy. Ultrathin 
sections (80 nm) were mounted to copper grids, counterstained with lead citrate, and 
analyzed by electron microscopy. 
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4.5 Immunohistochemistry   
 
For identification of endogenous antibodies on nerve cross-sections or teased fibers, PFA-
fixed samples were blocked for 30 min with 10% bovine serum albumin (BSA) and 1% 
normal goat serum (NGS) in 0.1M PBS, followed by incubation with Cy3-conjugated goat 
anti-mouse IgG-Fc antibodies in 1% BSA and 1% NGS in 0.1M PBS for 1 h at room 
temperature (RT). Alternatively, samples were incubated over night with non-coupled 
rabbit anti-mouse IgG-Fc antibodies at 4°C. After washing steps with PBS corresponding 
Cy3-conjugated secondary antibodies were added for 1 h at RT.  
 
To investigate if antibodies are bound to extra- or intracellular domains, unfixed and non-
permeabilized native sciatic nerves were incubated free floating in a 96-well plate (Klein et 
al., 2015). IgG-Fc staining was performed equally as described above. To control for 
intracellular antibody binding, nerve fibers were permeabilized by repeated cycles of 
freezing in liquid nitrogen and thawing. Incubation with rabbit anti-mouse -III-Tubulin 
and detection with the corresponding Cy3-conjugated secondary antibodies for 1 h was 
performed as a positive control. 
 
Complement deposition was identified on teased fiber preparations as described elsewhere 
(Klein et al., 2015). Briefly, samples were fixed in acetone (10 min, -20°C), blocked with 
5% NGS with 0.3% TritonX-100 in 0.1M PBS, and incubated with FITC-conjugated goat 
anti-mouse C3 antibodies in 1% NGS with 0.3% TritonX-100 in 0.1M PBS for 1 h at RT. 
As positive controls, single teased fibers from distal parts of lesioned sciatic nerves (3 days 
after crush) were identically treated. As another positive control, diaphragms, incubated ex 
vivo with anti-ganglioside monoclonal antibodies and normal human serum (Goodyear et 
al., 1999) (provided by Dr. Rhona McGonigal) were investigated for complement 
deposition in the same way, whereby postsynaptic terminals were identified with Alexa 
Fluor 555-conjugated -Bungarotoxin. 
 
For staining of endoneurial macrophages, fresh-frozen samples were fixed in acetone, 
blocked with 5% BSA in 0.1M PBS followed by an avidin-biotin blocking step. 
Afterwards biotinylated rat anti-F4/80 primary antibodies in 1% BSA in 0.1M PBS were 
applied for 1 h at RT and detected by Cy3-conjugated Streptavidin (1:100, CED-
CLCSA1010, Biozol).  
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For identification of macrophage polarization, immunohistochemical stainings against 
CD86 (M1-marker) or CD206 (M2-marker) were performed on fresh frozen nerve 
samples. Sections were fixed in acetone followed by blocking with 5% BSA in 0.1 M PBS.  
After incubation over night at 4°C, primary antibodies (in 0.1 M PBS containing 1% BSA) 
were detected by the corresponding Cy3-conjugated secondary antibodies. In case of 
CD206 labeling, 0.3% TritonX-100 was added to the blocking and antibody solutions.  
 
To quantify T-lymphocytes, fresh frozen nerve sections were treated the same way as 
described before (see section CD86) with primary antibodies (CD4, CD8) over night and 
detection with corresponding Cy3-conjugated secondary antibodies the next day. 
 
In all cases nuclei were visualized by incubation with DAPI (1:500000, D9542, Sigma-
Aldrich) for 10 min at RT.  
 
Immunohistochemical stainings against B-lymphocytes were performed on cross-sections 
of the spleen. Therefore, fresh-frozen samples were fixed in acetone, blocked with 5% 
BSA in 0.1M PBS and incubated with rat anti-B220/CD45R primary antibodies in 1% 
BSA in 0.1M PBS over night at 4°C and detected by Cy3-conjugated secondary antibodies.  
 
Immunohistochemistry for SMI32 (recognizing non-phosphorylated neurofilaments) as a 
marker for axonal perturbation was performed on femoral nerve cross-sections as 
previously described (Klein et al., 2014). Briefly, after acetone fixation and blocking with 
5% BSA and 5% NGS with 0.2% TritonX-100 in 0.1M PBS (30 min at RT) respective 
primary antibodies (SMI32, P0) were incubated over night at 4°C in 1% BSA 1% NGS 
with 0.2% TritonX-100 in 0.1M PBS and detected by corresponding secondary antibodies. 
 
To study muscle innervation, flexor digitorum brevis cross-sections were blocked with 5% 
BSA with 0.3% TritonX-100 in 0.1M PBS and, for visualization of presynaptic terminals, 
incubated with a guinea pig anti-synaptophysin primary antibody at 4°C over night in 1% 
BSA with 0.3% TritonX-100 in 0.1M PBS followed by incubation with Cy3-conjugated 
donkey anti-guinea pig IgG secondary antibodies. Postsynapses were labeled with Alexa 
Fluor 488-conjugated α-Bungarotoxin (1:300, B-13422, Molecular Probes). At least 80 
neuromuscular junctions per animal were quantified and categorized as being either 
innervated or denervated/partially denervated. 
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All samples were embedded after a final washing step with either Aqua-Poly/Mount
®
 
(Polysciences) or DABCO and encircled with Vitro-Clud
® 
(Langenbrinck). Detailed 
information about the antibodies used in this study can be found in appendix 8.5. 
 
Digital fluorescence microscopic images were acquired using an Axiophot 2 microscope 
(Zeiss) equipped with a CCD camera (Visitron Systems) and afterwards processed with 
Photoshop CS3 (Adobe). In case of P0/SMI32 immunohistochemistry, images were 
acquired on a FluoView FV1000 confocal microscope and processed using FluoView 
software (Olympus Germany). For quantification of immune cells (CD4, CD8, CD86, 
CD206, F4/80), whole nerve cross-sections were analyzed and the mean number of 
corresponding cells per section in seven to ten consecutive sections per animal was 
calculated. IgG fluorescence intensity in the endoneurium of femoral quadriceps nerve 
cross-sections was measured with ImageJ (NIH) as described elsewhere (Klein et al., 
2015). Images were converted to 32 bit grayscale images and the mean gray value of the 
endoneurium was calculated to determine immunoreactive signals, taking the mean gray 
value of P0wt nerves as a reference value of ‘1’. Data is shown as the mean of n = 2 per 
genotype of three repeated stainings. At least three sections per animal and experiment 
were analyzed.  
 
4.6. RNA extraction and semi-quantitative real-time PCR 
 
RNA extraction and semi-quantitative real-time PCR (qRT-PCR) were performed as 
previously described (Fischer et al., 2008a). Briefly, snap frozen femoral quadriceps nerves 
were homogenized (ART Labortechnik) in TRIzol
®
 reagent (Invitrogen). Total RNA was 
isolated by Phenol-Chloroform extraction, phase separation and subsequent precipitation 
according to the guidelines of manufacturer. Additionally, 20 µg of Glycogen (Roche) was 
added to each sample before RNA-precipitation. Precipitated RNA was subsequently 
solubilized in 10 µl DEPC-H2O and incubated at 60°C for 10 min. Afterwards the 
concentration and the quality of RNA were measured using a photometer (Eppendorf). 
 
0.5 μg of RNA was reverse transcribed in a 100 μl reaction using random hexamer primers 
and MuLV reverse transcriptase (Applied Biosystems) according to the guidelines of 
manufacturer with the following cycler conditions: 10 min at 25°C; 60 min at 37°C; 5 min 
at 95°C. 1.5 µl of the resulting complementary DNA (cDNA) was analyzed in duplicates 
or triplicates by semi-quantitative real-time PCR using pre-developed TaqMan
®
 assays 
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(eukaryotic 18s rRNA, 4319413E; murine Arginase1, Mm00475988_m1; CD86, 
Mm00444543; CD206, Mm00485148_m1; CSF-1, Mm00432688_m1, FcRI, 
Mm00438874_m1; FcRIIB, Mm00438875_m1; FIZZ1, Mm00445109; IFN, 
Mm01168134_m1; IL-1, Mm00434228_m1; IL-6, Mm00446190_m1; iNOS, 
Mm00440485_m1; LIF, Mm00434761_m1; CCL2/MCP-1, Mm99999056_m1; TGF-, 
Mm00441724_m1; TNF, Mm00443258_m1; TREM-2, Mm00451744_m1; Ym1, 
Mm00657880_mH) and TaqMan
®
 universal PCR master mix (Applied Biosystems) 
according to the instructions of the manufacturers (10 µl per sample). Data sets were 
analyzed with the ΔΔCT method in relation to the corresponding 18s RNA content and 
were related to a wildtype sample. 
 
4.7. Western blot analysis  
 
Dissected femoral quadriceps nerves were snap frozen in liquid nitrogen. After sonification 
(Sonoplus HD60, Bandelin electronic) in 100 µL RIPA lysis buffer per 10 mg tissue, 
protein concentrations were determined by a Lowry assay (Sigma-Aldrich) using BSA as 
standard (Lowry et al., 1951). Samples were combined with 6x Laemmli sample buffer 
(Laemmli, 1970) and denatured for 5 min at 95°C. Equal amounts of proteins were 
resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE with 
10% acrylamide) using a Mini-PROTEAN3 module (Bio-RAD). Afterwards, samples were 
transferred to a nitrocellulose membrane (Hartenstein) using a Mini-Trans-Blot® module 
(Bio-RAD) at 400 mA with the addition of an ice-cooling unit and visualized with Ponceau 
S (Carl Roth). After three washing steps in PBST, membranes were blocked with 5% 
skimmed milk in PBST and incubated with either goat anti-C3 (1:500, 0855500, MP 
Biomedicals) or rabbit anti-ERK1/2 (1:10000, sc-94, Santa Cruz) antibody solution over 
night at 4°C. After several washing steps in PBST the corresponding horseradish 
peroxidase (HRP)-conjugated secondary antibodies (anti-goat: 1:10000, 705-035-147, 
Jackson Immunoresearch; anti-rabbit: 1:5000, NA9340V, GE Healthcare) were probed for 
1 h at RT. After final incubation in PBST immune reactions were determined by 
incubation with ECL reagents for 1 min and chemiluminescence detected by ECL 
hyperfilm (GE Healthcare). Endogenous antibodies were detected by directly labelled 
HRP-anti-mouse IgG-Fc antibodies (1:5000, 115-035-008, Dianova) over night at 4°C or 
for 2 h at room temperature. To determine IgG- or C3-immunoreactivity in nerve lysates, 
densitometric analyses were performed with Image J (NIH). The specific band for C3-
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immunoreactivity was detectable at approximately 65kDa, the estimated molecular size of 
the C3b fragment-chain), an activated form of C3. P0wt nerves were taken as a 
reference. Results from two experiments are shown and depicted as the ratio of IgG or C3 
to ERK1/2, respectively. 
 
4.8. Electron microscopy and morphological analysis  
 
Samples were processed as described above and multiple image alignments were acquired. 
Abnormally myelinated fibers, consisting of thinly and demyelinated axons, onion bulbs, 
periaxonal vacuoles and foamy macrophages were quantified in relation to the total 
number of axons in cross-sections of the femoral quadriceps nerve. The g-ratio was 
determined by dividing the diameter of the axon by the fiber diameter (axon including its 
myelin sheath). At least 125 fibers per animal were randomly selected and measured. 
Analysis was performed using a ProScan Slow Scan CCD camera mounted to a Leo 906E 
electron microscope (Zeiss) with corresponding iTEM software (Olympus Soft Imaging 
Solutions GmbH). 
 
4.9. Reconstitution experiments 
 
150 μg of mouse IgGs (PMP01, Serotec) or mouse anti-keyhole limpet hemocyanin 
(KLH)-antibody (orb11067, Biorbyt) or 50 µg mouse IgG Fc-fragments (31205, Pierce) 
were injected into the tail vein (i.v.) once or at four consecutive weeks followed by 
analysis one week later. After dissection and tissue processing, specific binding of 
antibodies in peripheral nerves was controlled by immunohistochemistry and Western blot 
analysis (see above).  
 
4.10. Nerve conduction studies 
 
Mice were anesthetized by an intraperitoneal injection of a mixture of ketavet and xylavet 
(10 μl per g body weight), placed under a heating lamp to avoid hypothermia and body 
temperature was controlled before and after measurements (34-36°C). Neurological 
properties of the left sciatic nerve were measured as described previously (Zielasek et al., 
1996). In short, after supramaximal stimulation of the tibial nerve at the ankle (distal) and 
the sciatic nerve at the sciatic notch (proximal) with monopolar needle electrodes 
compound muscle action potential (CMAP) amplitudes [mV] were recorded at the hind 
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paw muscles using steel needle electrodes. Furthermore, distal, proximal and F-wave 
latencies [ms] were measured as well as the distance between stimulation sites and the 
corresponding nerve conduction velocity (NCV) [ms] was calculated. All neurographic 
recordings were performed with a digital Neurosoft-Evidence 3102 electromyograph 
(Schreiber & Tholen Medizintechnik). Nerve conduction studies were approved by the 
local authorities.  
 
4.11. Statistical analysis 
 
Data sets were controlled for normal distribution by the Shapiro-Wilk test, and variance 
homology was determined by the Levene test. The comparison of more than two groups 
with normally distributed data (parametric) was performed by a one-way ANOVA, 
followed by Tukey`s post hoc-test or Bonferroni-Holm correction. In case of non-normally 
distributed data sets, the nonparametric Kruskal-Wallis-test with Bonferroni-Holm 
correction was applied. Significance levels (*, # P < 0.05; **, # # P < 0.01; ***, # # # P < 
0.001) are indicated together with the applied statistical tests within the figure legends. 
Measurements and quantifications are shown as mean + SD unless otherwise mentioned. 
Statistical analyses were performed using PASW Statistics 18 (SPSS, IBM) software and 
diagrams were generated with Microsoft Excel 2007. All experiments were performed by 
investigators unaware of the genotypes of the analyzed mice.  
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5. Results   
 
5.1. Antibodies accumulate in peripheral nerves of P0het myelin mutant mice  
 
Several studies revealed the pathogenic role of secondary low grade inflammation - 
implicating macrophages and lymphocytes - in mouse models for CMT1 (Martini et al., 
2013).  Whereas macrophages were clearly identified as robust disease modifiers, the exact 
function of the adaptive immune system in the pathogenesis of CMT1B is not clearly 
understood. Interestingly, a previous study demonstrated that endogenous antibodies bound 
to injured myelinated fibers act as important co-mediators for Wallerian degeneration after 
peripheral nerve injury, contributing to the activation of macrophages and rapid clearance 
of myelin (Vargas et al., 2010). Based on these observations, the pathogenic impact of 
endogenous antibodies in a mouse model for CMT1B (P0het mice) was investigated. 
 
To detect possible antibody depositions in peripheral nerves, immunohistochemical 
stainings for IgGs on femoral nerve cross-sections from 6-month-old P0het mutant mice 
and wildtype (P0wt) littermates were performed. A strong IgG-immunoreactivity was 
detectable in the perineurium of femoral quadriceps nerves from both P0wt mice and P0het 
mutants (Fig. 1A). In contrast, the endoneurium of mutant nerves revealed a higher 
antibody deposition compared to wildtype littermates. This could be confirmed by 
measuring the signal intensity of IgG-immunoreactivity in P0het and P0wt mice (Fig. 1B). 
Of note, in the saphenous nerve, the non-affected sensory branch of the femoral nerve 
(Carenini et al., 2001; Fischer et al., 2008b), this prominent antibody deposition could not 
be detected in P0het mutant mice (Fig. 1A).  
 
Moreover, IgG-immunocytochemistry was also performed on single teased fiber 
preparations to detect a preferential deposition along myelinated fibers. A stronger 
deposition along nerve fibers could be confirmed in P0het mice compared to wildtype 
littermates, with strongest IgG-immunoreactivity at nodes of Ranvier (Fig. 2A). To further 
confirm whether endogenous antibodies bind to extra- or intracellular domains of nerves 
from P0het mice, fibers of unfixed and non-permeabilized sciatic nerves were separated 
into small fiber bundles and stained free floating for IgG and -III-Tubulin. Endogenous 
antibodies could be observed along myelinated nerve fibers indicating extracellular 
deposition. In contrast, -III-Tubulin-immunoreactivity was confined to some axonal 
profiles at nodes of Ranvier (Fig. 2B), possibly reflecting the vulnerability of this structure 
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by mechanical teasing and resulting in a higher accessibility to intracellular domains. To 
control for binding to intracellular domains, nerve fibers were repeatedly frozen in liquid 
nitrogen to allow permeabilization followed by incubation with antibodies to IgG or -III-
Tubulin. As expected -III-Tubulin staining showed an extended immunoreactivity along 
the entire axon including internodes, while IgG-immunoreactivity was still visible along 
the outer margins of the myelinated fibers (Fig. 2B). These results suggest that endogenous 
antibodies bind to extracellular surface structures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Antibodies accumulate in peripheral nerves of 6-month-old P0het mice. A. 
Immunohistochemical localization of endogenous antibodies (IgG) in femoral quadriceps (q) and 
saphenous nerves (s) from 6-months-old wildtype mice (P0wt) and myelin mutants (P0het). Note 
the prominent labeling of the endoneurium in femoral quadriceps nerve cross-sections of mutants 
in contrast to wildtype mice. RAG1-deficient mice (deficient for T- and B-lymphocytes) are, 
expectedly, devoid of antibody deposition. Scale bar, 20μm.  B. IgG fluorescence intensity in the 
endoneurium of femoral quadriceps nerve cross-sections is shown as the mean gray value, taking 
P0wt nerves as a reference. n = 2 animals per genotype were analyzed within 3 repeated stainings 
and measurements. C. Immunohistochemical localization of endogenous antibodies (IgG) in 
femoral quadriceps (q) and saphenous nerves (s) from 1-month-old wildtype mice (P0wt) and 
myelin mutants (P0het). Note similar endoneurial immunoreactivity in comparison to 6-months-old 
mutants (see A) but the much lower intensity of the perineurium. Scale bar, 20μm.   
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Fig 2 
 
 
 
 
 
 
 
Figure 2: Antibody deposition at extracellular domains in peripheral nerves of 6-month-old 
P0het mice. A. Immunocytochemical staining against IgG on single teased fiber preparations. Note 
preferential deposition of antibodies in the nodal regions and the generally stronger signal along 
myelinated fibers in P0het mice compared to wildtype littermates. Nerve-specific antibodies are not 
detectable in RAG1-deficient mice. The corresponding phase contrast micrograph displays the 
teased fiber with a node of Ranvier (arrowhead). Scale bar, 20μm. B. Immunocytochemical 
staining against IgG or -III-Tubulin on unfixed and non-permeabilized native sciatic nerve fibers 
of P0het mice (left and middle column). Note IgG-immunoreactivity along the outer margins of the 
myelinated nerve fibers and at nodes of Ranvier (arrowhead, left column) whereas -III-Tubulin-
immunoreactivity is confined to some axonal profiles at nodes of Ranvier (arrowheads, middle 
column), likely due to the vulnerability of this structure upon teasing. In the permeabilized sciatic 
nerve samples of P0het mice, -III-Tubulin-immunoreactivity is visible along the entire axon 
(arrows, lower right column) and no longer confined to nodes (see middle columns), whereas IgG-
immunoreactivity is still detectable along myelinated fibers (upper right column). White dashed 
lines indicate outer margins of myelinated nerve fibers. Scale bar, 20µm. C. Western blot analysis 
of P0wt and P0het femoral quadriceps nerve lysates showing stronger IgG signal in mutant mice. 
RAG1-deficient mice show no antibody signal. ERK1/2 serves as a loading control. D. 
Densitometric analysis of IgG-immunoreactivity in Western blots from P0het mutant mice and 
P0wt littermates, taking ERK1/2 signal as a reference (loading control). Results of n = 2-3 from 
two independent experiments are depicted.   
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To corroborate the immunocytochemical findings, Western blot analysis of peripheral 
nerve extracts were performed using antibodies to mouse IgG and IgM subtypes. An 
increased IgG (Fig. 2C) and IgM signal (not shown) was found in P0het mice in 
comparison to P0wt mice and in the respective densitometric quantification (Fig. 2D), 
supporting the immunocytochemical observations. Specificity of the antibody deposition 
was controlled by immunocytochemistry and Western blot analysis in RAG1-deficient 
mice, lacking T- and B-lymphocytes, and therefore antibodies. As expected, antibody 
deposition was undetectable in peripheral nerves (Fig. 1 and 2). Next, 1-month-old P0het 
and P0wt mice were investigated to determine whether endogenous antibodies are present 
at early disease course. At this time point in the disease, features typical for demyelination 
are morphologically not yet visible. Indeed, by immunohistochemsitry (Fig. 1C) and 
Western blot analysis (not shown), already at this age a similarly elevated IgG-
immunoreactivity in the mutant nerves comparable to 6 months of age was detectable. 
Antibody deposition was additionally investigated by immunohistochemistry on femoral 
nerve cross-sections from 12-month-old P0wt and P0het mice, a time point with a fully 
developed demyelinating phenotype. Comparable with observations in mice at the age of 6 
months, a strong IgG-immunoreactivity was detectable in the perineurium of femoral 
nerves of both investigated groups. Similarly, the endoneurium of femoral quadriceps 
nerves in P0het mutant mice revealed a higher IgG-immunoreactivity compared to 
wildtype littermates (Fig. 3A). A stronger antibody deposition along nerve fibers could be 
confirmed in P0het mice compared to P0wt mice by IgG-immunocytochemistry on single 
teased fiber preparations (Fig. 3B). Together these data suggest that specific endogenous 
antibodies bind to extracellular domains of mutant Schwann cells in peripheral nerves of 
myelin mutant mice as a potential early prerequisite to modulate disease pathogenesis in an 
animal model for CMT1B.  
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Figure 3: Antibodies accumulate in peripheral nerves of 12-month-old P0het mice. A. 
Immunohistochemical localization of endogenous antibodies (IgG) in femoral quadriceps (q) and 
saphenous nerves (s) from 12-month-old wildtype mice (P0wt) and myelin mutants (P0het). Note 
strong immunoreactivity in the perineurium and similarly prominent labeling of the endoneurium in 
P0het mutants in contrast to P0wt mice, as in 6-month-old mice (see Fig. 1). B. 
Immunocytochemical staining against IgG on single teased fiber preparations. Note the preferential 
deposition of antibodies in the nodal regions and the generally stronger immunoreactivity along 
myelinated fibers in P0het mice compared to wildtype mice, similar as in 6-months-old mice (see 
Fig. 2). Scale bars, 20μm. 
 
 
5.2. Lack of evidence for complement deposition 
 
Previous studies demonstrated that antibody deposition, either at the outer surface of 
Schwann cells, or at nodes of Ranvier, can lead to activation of the complement system to 
trigger subsequent nerve damage (Willison et al., 2008; Yuki and Hartung, 2012; Willison 
and Goodyear, 2013). Moreover, it was shown that the complement system is involved in 
the efficient removal of myelin and the recruitment of macrophages in Wallerian 
degeneration (Dailey et al., 1998; Ramaglia et al., 2007). Therefore, it was investigated if 
C3, a central component of the classical and alternative complement pathway, was 
detectable in P0het mutant nerve fibers at 6 months of age by immunocytochemistry using 
a C3-specific antibody. C3-deposition was strongly detectable on nerve fibers of crushed 
nerves and on explanted diaphragms incubated with anti-ganglioside antibodies and normal 
human serum (Fig. 4), which both served as a positive control for complement activation, 
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as previously described (Goodyear et al., 1999; Ramaglia et al., 2007). However, no 
complement deposition was observable on wildtype or mutant nerve fibers (Fig. 4) which 
could also be confirmed by Western blot analysis (Fig. 5). Activation of the complement 
cascade was also investigated in 12-month-old mice by Western blot analysis. Whereas 
C3-immunoreactivity was amply detectable in lysates of P0wt mice after sciatic nerve 
crush, again serving as a positive control, nerve lysates of P0het mice showed no 
complement activation (Fig. 5), suggesting no involvement of the complement pathway 
during disease pathogenesis in CMT1B mutant mice.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Lack of evidence for complement deposition in peripheral nerve fibers of 6-month-
old P0het mice. A. Immunocytochemical staining against C3 on single teased fiber preparations.  
Complement deposition is detectable in teased fibers from crushed wildtype sciatic nerves (3 days 
post crush, DPC), but not in nonlesioned sciatic nerves from 6-month-old P0wt and P0het mice. 
Corresponding phase contrast (PC) micrographs are also shown. B. Immunohistochemical staining 
against C3 (green) and -Bungarotoxin (BTX, red, postsynapse) on diaphragm cross-section. 
Complement deposition is found at presynaptic terminals and perisynaptic Schwann cells 
(Goodyear et al., 1999).  Blue profiles in merged micrographs are DAPI-labeled nuclei. Scale bars, 
5µm. 
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Figure 5: Lack of evidence for complement deposition in peripheral nerve fibers of 6- and 12-
month-old P0het mice. A. Western blot analysis of wildtype (P0wt) and P0het mutant mice at 6 
and 12 months of age.  Complement activation (C3) is detectable in nerve lysates from crushed 
wildtype sciatic nerves (3 days post crush), but not in nonlesioned sciatic nerve lysates from 6- and 
12-month-old P0wt and P0het mice. ERK1/2 serves as a loading control. B. Densitometric analysis 
of C3-immunoreactivity in Western blots from P0het mutant mice and P0wt littermates at 6 and 12 
months of age, taking ERK1/2 signal as a reference (loading control). Results of n = 2 per group 
from two experiments are depicted.   
 
 
5.3. Reduced macrophage numbers in peripheral nerves of 6-month-old P0het JHD-/- 
mice 
 
As a next step, P0het mice were crossbred with JHD-deficient mutants that specifically 
lack B-lymphocytes and are incapable to produce antibodies in order to identify the 
pathogenic role of endogenous antibodies in a mouse model for CMT1B. As expected, 
JHD-/- mice lacked B-lymphocytes in the spleen and antibodies in peripheral nerves as 
demonstrated by immunohistochemistry and Western blot analysis (Fig. 6). 
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Figure 6: JHD-deficient mice lack B-lymphocytes and antibodies. A. Immunohistochemical 
staining against B220-positive B-lymphocytes in wildtype (P0wt JHD+/+) and JHD-deficient mice. 
Note lack of immunoreactivity in JHD-deficient mice. Scale bar, 50µm. B. IgG deposition was not 
detectable in 6-month-old femoral quadriceps (q) and saphenous nerves (s) from JHD-deficient 
mice. The corresponding phase contrast (PC) micrograph is also shown. Scale bar, 20µm. C. 
Western blot analysis confirms the lack of endogenous antibodies in JHD-deficient mice. ERK1/2 
serves as a loading control. 
 
 
To gain further insights into the pathogenic role of endogenous antibodies, the number of 
macrophages was investigated in 6-month-old wildtype, single and double mutant mice 
(Fig. 7). As previously shown, increased macrophage numbers and subsequent 
demyelination occur in femoral quadriceps nerves of P0het mice (Carenini et al., 2001; 
Fischer et al., 2008b). Corroborating these results, the number of macrophages was 
significantly elevated in femoral quadriceps nerves of P0het mice at 6 months of age 
compared with age-matched wildtype littermates (Fig. 7A, B). Whereas no effect on 
macrophage numbers was detectable in P0wt JHD-/- mice, P0het JHD-/- mice revealed a 
significantly attenuated elevation of F4/80-positive macrophages (Fig. 7A, B). In 
pathologically non-affected cutaneous saphenous nerves that also lack extensive antibody 
deposition (see Fig. 1) the number of macrophages was not altered in single and double 
mutant mice (Fig. 7A, B). Moreover, macrophage activation, represented by a myelin-
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laden (‘foamy’) appearance, was investigated by electron microscopy. A substantial 
number of activated macrophages was only detectable in P0het JHD+/+ mice, whereas all 
other genotypes, including P0het JHD-/- mice lacked these foamy macrophages (Fig. 7C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Reduced macrophage numbers in 6-month-old P0het JHD-/- mice. A. 
Immunohistochemistry against macrophages (F4/80) in femoral nerve cross-sections from 6-
month-old wildtype (P0wt JHD+/+), single (P0het JHD+/+) and double mutant mice (P0het     
JHD-/-). Representative micrographs are shown. Dashed circles indicate femoral quadriceps (q) 
and saphenous nerves (s). Scale bar, 20μm. B. Quantification of F4/80-positive profiles showing a 
significant reduction of macrophage numbers in the femoral quadriceps nerve from P0het JHD-/- 
double mutants in comparison to single mutants. In the saphenous nerve the number of 
macrophages is not increased in mutants. n = 4 - 5; one-way ANOVA with Tukey post hoc test. # 
(significant difference to P0wt JHD+/+), * (significant difference between P0het mutant groups). #, 
* P < 0.05; ##, ** P < 0.01; ###, *** P < 0.001. C. Quantification of foamy macrophages in 
femoral quadriceps nerve cross-sections reveals an absence of phagocytosing macrophages in 
nerves from P0het JHD-/- mice. n = 4 - 5; Kruskal-Wallis test with Bonferroni-Holm correction. # 
(significant difference to P0wt JHD+/+), * (significant difference between P0het mutant groups). #, 
* P < 0.05. n.d. (not detected). 
 
 
In order to determine the polarization status of macrophages immunohistochemical 
stainings were performed against CD86 and CD206 (mannose receptor), markers for M1- 
or M2-activation, respectively (Kigerl et al., 2009). In femoral quadriceps nerve cross-
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sections from 6-month-old P0het JHD+/+ mice the number of CD86-positive cells was 
significantly increased compared to wildtype littermates (Fig. 8A). Interestingly, the 
numbers of M1-polarized, CD86-positive cells was significantly reduced in P0het JHD-/- 
mice (Fig. 8A). In contrast, CD206-positive cells were not elevated in numbers in P0het 
JHD+/+ mice compared to wildtype littermates and did not significantly differ between 
P0het JHD+/+ and P0het JHD-/- mice (Fig. 8B). These results suggest that the reduced 
number of F4/80-positive macrophages in P0het JHD-/- mice at 6 months of age is 
preferentially due to a reduced number of CD86-positive, M1-polarized cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Altered macrophage polarization and reduced number of CD4-positive T-
lymphocytes in 6-month-old P0het JHD-/- mice. A. Quantification of CD86-positive cells (M1) 
in femoral quadriceps nerve cross-sections of 6-month-old mice. P0het JHD+/+ mice show 
significantly increased number of CD86-positive cells compared to P0wt JHD+/+ mice. Consistent 
with macrophage numbers, M1-polarized cells are significantly reduced in P0het JHD-/- mice 
compared to P0het JHD+/+ single mutants. B. Quantification of CD206-positive cells (M2) in 
femoral quadriceps nerve cross-sections of 6-month-old mice. No significant alterations in the 
number of CD206-positive cells can be detected in the investigated groups at 6 months of age. n = 
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3 - 5; one way ANOVA with Bonferroni-Holm correction, # (significant difference to P0wt 
JHD+/+), * (significant difference between P0het mutant groups). #, * P < 0.05; ##, ** P < 0.01; 
###, *** P < 0.001. C. Quantification of CD4-positive T-lymphocytes in femoral quadriceps nerve 
cross-sections of 6-month-old mice. CD4-positive lymphocytes are significantly elevated in P0het 
JHD+/+ mutant mice compared to wildtype littermates, but significantly reduced in P0het JHD-/- 
mice.  n = 3 - 6; Kruskal-Wallis test with Bonferroni-Holm correction, # (significant difference to 
P0wt JHD+/+), * (significant difference between P0het mutant groups). #, * P < 0.05.   
 
 
As a next step, T-lymphocytes as possible mediators of the pathogenesis were investigated. 
CD8-positive T-lymphocytes were scarcely detectable in peripheral nerves of P0het 
JHD+/+ and P0het JHD-/- mice at 6 months of age (not shown) and therefore not further 
considered to contribute to disease progression. However, quantification of CD4-positive 
T-lymphocytes revealed a significant elevated number in P0het JHD+/+ mice compared to 
wildtype littermates and P0het JHD-/- double mutants (Fig. 8C), suggesting that JHD 
deficiency results in a reduction of immune-related cells in P0het mice. 
 
 
5.4. JHD deficiency ameliorates the demyelinating phenotype in 6-months-old P0het 
mutant mice 
 
Demyelination is a typical feature in the P0het CMT1B mouse model (Carenini et al., 
2001; Fischer et al., 2008b). Therefore, it was investigated whether the absence of 
antibodies in P0het JHD-/- mice leads to reduced signs of demyelination. Quantification by 
electron microscopy demonstrated a significant reduction of abnormally myelinated fibers 
(comprising de- and thinly myelinated axons) and supernumerary Schwann cells (‘onion 
bulbs’) in P0het JHD-/- mice compared to P0het JHD+/+ mice at 6 months of age (Fig. 
9A-C). Of note, JHD deficiency had no effect on the nerve structure in P0wt mice (Fig. 
9B-C). Moreover, calculation of the g-ratio (axon diameter/fiber diameter) revealed a 
significantly less reduced myelin thickness in P0het JHD-/- compared to P0het JHD+/+ 
mice (Fig. 9D) further supporting the hypothesis that endogenous antibodies might 
contribute to macrophage-mediated demyelination in a mouse model for CMT1B.    
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Figure 9: Ameliorated myelin degeneration in 6-month-old P0het JHD-/- mice. A. 
Representative ultrathin sections of femoral quadriceps nerves from 6-month-old wildtype (P0wt 
JHD+/+), single (P0het JHD+/+) and double mutant mice (P0het JHD-/-). Black asterisks indicate 
abnormally myelinated fibers, and arrows supernumerary Schwann cells (‘onion bulbs’). Note an 
asymmetric inclusion of compacted myelin, likely at the juxtaparanode, in P0het JHD-/- mice 
(white asterisk) as described previously (Martini et al., 1995). Scale bar, 5μm. B. - C. 
Quantification of abnormally myelinated fibers (B) and onion bulbs (C) demonstrate significantly 
ameliorated demyelination and improved myelin integrity in P0het JHD-/- double mutants in 
comparison to P0het JHD+/+ mice. n = 4 - 5; Kruskal-Wallis test with Bonferroni-Holm correction, 
# (significant difference to P0wt JHD+/+), * (significant difference between P0het mutant groups). 
#, * P < 0.05. n.d. (not detected). D. Quantification of the g-ratio (axon diameter/fiber diameter) 
demonstrates a significant increase in myelin thickness in P0het JHD-/- compared to P0het JHD+/+ 
mice. n = 4 (125-135 axons per animal); two-tailed Student’s t-test. * P < 0.05. 
 
 
5.5. Passive transfer of antibodies reverts the ameliorated demyelinating phenotype in 
6-month-old P0het JHD-/- mice  
 
To further validate the hypothesis and clarify the role of endogenous antibodies in the 
pathogenesis of CMT1B, reconstitution experiments into P0het JHD-/- mice were 
performed in order to study if antibodies are capable to reverse the observed beneficial 
effects of JHD deficiency. Mice at the age of 6 months received i.v. injections of IgGs 
either once or on four consecutive weeks and were analyzed afterwards. As detected by 
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immunohistochemistry, passive transfer into P0wt JHD-/- and P0het JHD-/- mice led to an 
accumulation of IgGs in peripheral nerves comparable to corresponding JHD-positive 
controls, although at a weaker level. This indicates that injected IgGs are capable to enter 
the nerve and bind to their respective targets (Fig. 10A). Expectedly, P0het JHD-/- mice 
that received four weekly IgG-injections showed a stronger IgG deposition in the 
endoneurium compared to mice that received only a single passive transfer (Fig. 10A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Antibodies accumulate in peripheral nerves after passive transfer and lead to 
increased macrophage numbers. A. Immunohistochemical localization of antibodies in femoral 
quadriceps (q) and saphenous nerves (s) from 6-month-old P0wt JHD-/- (7 days post injection, 
DPI) and P0het JHD-/- mice (7DPI and 28DPI) after systemic injection of IgGs. Note stronger IgG-
immunoreactivity in the endoneurium of P0het JHD-/- mice that received 4 weekly IgG-injections 
within 28 days (28DPI). Scale bar, 20μm. B. Quantification of F4/80-positive profiles in non-
injected control and reconstituted mice showing an increase of macrophage numbers in the femoral 
quadriceps nerve from P0het JHD-/- mutants after IgG reconstitution. n = 3 - 5; one-way ANOVA 
with Bonferroni-Holm correction. * P < 0.05. C. Quantification of foamy macrophages reveals an 
increase of phagocytosing macrophages in the femoral quadriceps nerve from P0het JHD-/- mice 
after IgG reconstitution. Note also the presence of phagocytosing macrophages in control-
reconstituted animals (+KLH, +IgG Fc). n = 3 - 5; Kruskal-Wallis test with Bonferroni-Holm 
correction. * P  < 0.05. n.d. (not detected). For comparison, data from P0het JHD+/+ and P0het 
JHD-/- mice, as shown in figure 7 are presented here again. 
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Consistent with an increased antibody deposition in nerve sections after passive antibody 
transfer, elevated numbers of F4/80-positive macrophages and foamy macrophages were 
detectable in P0het JHD-/- mice (Fig. 10B, C). Interestingly, these numbers were 
comparable to numbers obtained in age-matched P0het JHD+/+ mutants, suggesting an 
activated macrophage response after IgG injections. Of note, antibody reconstitution had 
no effect on macrophage numbers in P0wt JHD-/- mice (not shown). As a next step, nerve 
fiber damage was quantified by electron microscopy in order to analyse the pathogenic 
impact of passive antibody transfer. P0wt JHD-/- showed no pathological alterations after 
IgG injections (Fig. 11A). However, passive antibody transfer reverted the ameliorated 
phenotype in P0het JHD-/- mice, as determined by an increased number of abnormally 
myelinated fibers and supernumerary Schwann cells after IgG injections (Fig. 11B, C), 
suggesting that added antibodies can modulate macrophage-mediated demyelination.  
 
To study whether antigen specificity is necessary for the detrimental effect of antibodies, 
passive transfer experiments into P0het JHD-/- mice were performed using mouse 
antibodies that either show specificity for a non-mammalian antigen, like keyhole limpet 
hemocyanin (KLH), or antibody fragments lacking the antigen directed domain (mouse 
IgG Fc-fragments). As expected for both cases, no antibody deposition could be detected 
in peripheral nerves by immunohistochemistry (not shown). Unexpectedly, passive transfer 
of non-specific IgGs or mouse IgG Fc-fragments led to a slight, non-significant increase of 
total macrophage numbers in individual animals (Fig. 10B) together with an increase of 
phagocytosing macrophages (Fig. 10C). Consistent with this activated macrophage 
response, a mild increase in nerve fiber damage could be observed after reconstitution 
experiments with the above-mentioned antibodies and fragments (Fig. 11). These data 
suggest that non-specific IgGs can activate macrophages and contribute to demyelination 
in peripheral nerves of P0het mice, yet to a lesser extent.  
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Figure 11: Antibody reconstitution reverts the ameliorated demyelinating phenotype in 6-
month-old P0het JHD-/- mice. A. Representative ultrathin sections of femoral quadriceps nerves 
from 6-month-old IgG reconstituted P0wt JHD-/-, P0het JHD+/+ controls and IgG reconstituted 
P0het JHD-/- mice. Asterisks indicate abnormally myelinated fibers. Scale bar, 5μm. B. - C. 
Quantification of abnormally myelinated fibers (B) and signs of demyelination (onion bulbs) (C) in 
control and reconstituted mice reveal a significant aggravation of myelin degeneration in IgG 
reconstituted P0het JHD-/- mutants. Note also a non-significant trend of increased pathological 
alterations in control-reconstituted animals (+KLH, +IgG Fc). n = 3 - 5; Kruskal-Wallis test with 
Bonferroni-Holm correction. * P < 0.05; ** P < 0.01. For comparison, data from P0het JHD+/+ 
and P0het JHD-/- mice, as shown in figure 9 are presented here again.  
 
 
5.6. Increased macrophage numbers in peripheral nerves of 12-month-old P0het 
JHD-/- mice 
 
A robust and persistent reduction of macrophages and amelioration of the demyelinating 
phenotype could be demonstrated in P0het mice lacking both T-and B-lymphocytes at 12 
months of age (Schmid et al., 2000). Therefore the number of macrophages was 
investigated in femoral nerve cross-sections from 12-month-old mice. Confirming previous 
results (Fischer et al., 2008b), P0het single mutants showed increased numbers of 
macrophages compared to 6 months of age, reflecting the increased inflammatory reaction 
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with ongoing disease development (Fig. 12A, B). Unexpectedly, in P0het JHD-/- double 
mutants the number of macrophages was further elevated in the femoral quadriceps nerve 
(Fig. 12A, B), contrary to the observations at 6 months of age. This was also in line with 
electron microscopic analysis, as foamy macrophages were amply detectable in peripheral 
nerves of P0het JHD-/- mice (Fig. 12C), suggesting distinct effects on macrophage 
activation upon JHD deficiency during disease progression. Notably, in pathologically 
non-affected cutaneous saphenous nerves the number of macrophages was not altered in 
single and double mutant mice (Fig. 12A, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Increased macrophage numbers in 12-month-old P0het JHD-/- mice. A. 
Immunohistochemistry against macrophages (F4/80) in cross-sections of femoral nerves from 12-
month-old wildtype (P0wt JHD+/+), single (P0het JHD+/+) and double mutant mice (P0het     
JHD-/-). Representative micrographs are shown. Dashed circles indicate femoral quadriceps (q) 
and saphenous nerves (s). Note increased number of macrophages in P0het JHD-/- mice. Scale bar, 
20μm. B. Quantification of F4/80-positive profiles showing a significant increase of macrophage 
numbers in the femoral quadriceps nerve from P0het JHD-/- double mutants in comparison to 
P0het JHD+/+ single mutants. In the saphenous nerve the number of macrophages is not increased 
in mutants (n = 3 - 5); one-way ANOVA with Tukey post hoc test. # (significant difference to P0wt 
JHD+/+), * (significant difference between P0het mutant groups). #, * P < 0.05; ##, ** P < 0.01; 
###, *** P < 0.001. C. Quantification of foamy macrophages reveals the presence of 
phagocytosing macrophages in femoral quadriceps nerves from P0het JHD-/- mice. n = 4 - 7; 
Kruskal-Wallis test with Bonferroni-Holm correction. # (significant difference to P0wt JHD+/+), # 
P < 0.05; ## P < 0.01. n.d. (not detected). 
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5.7. JHD deficiency aggravates the demyelinating phenotype in 12-month-old P0het 
mutant mice 
 
Next, it was investigated whether the increased macrophage activation is reflected by 
augmented pathological alterations. Myelin degeneration was quantified in femoral 
quadriceps nerves by electron microscopy. Nerve fiber damage was increased in P0het 
JHD+/+ mice at 12 months compared to 6 months of age, reflecting the progressive disease 
course in the CMT1B neuropathy (Fig. 13). However, contrary to the ameliorating 
phenotype due to absence of endogenous antibodies at 6 months of age, the percentage of 
demyelinated fibers was significantly elevated in P0het JHD-/- mice compared to P0het 
JHD+/+ mice at 12 months of age (Fig. 13C). Of note, no effect on the nerve structure was 
detectable in P0wt JHD-/- mice (Fig. 13B, C). These observations suggest that JHD 
deficiency has an opposite effect in the disease course of P0het mice which results 
eventually in an aggravated phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Aggravated myelin degeneration in 12-month-old P0het JHD-/- mice. A. 
Representative ultrathin sections of femoral quadriceps nerves from 12-month-old wildtype (P0wt 
JHD+/+), single (P0het JHD+/+) and double mutant mice (P0het JHD-/-). Asterisks indicate 
demyelinated fibers. Scale bar, 5μm. B. - C. Quantification of thinly (B) and demyelinated fibers 
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(C) demonstrate a significant increase in demyelination and deteriorated myelin integrity in P0het 
JHD-/- mice in comparison to P0het JHD+/+ mice. n = 4 - 7; Kruskal-Wallis test with Bonferroni-
Holm correction, # (significant difference to P0wt JHD+/+), * (significant difference between 
P0het mutant groups). #, * P < 0.05; ##, ** P < 0.01. n.d. (not detected).  
 
 
It is assumed that Schwann cells can support axonal integrity and that prolonged 
demyelination or an impaired Schwann cell phenotype might lead to axonal perturbation 
(Martini, 2001; Nave, 2010). In order to study axonal damage, immunohistochemical 
stainings against non-phosphorylated neurofilaments (SMI32) (Groh et al., 2010) were 
performed on femoral nerve cross-sections of 12-month-old wildtype, single and double 
mutant mice. In P0het JHD+/+ mutants the number of SMI32-immunoreactive profiles was 
only slightly increased compared to P0wt JHD+/+ mice, reflecting the rather mild 
axonopathic phenotype in peripheral nerves of CMT1B mice at this age (Fig 14). However, 
P0het JHD-/- double mutants revealed a stronger SMI32-immunoreactivity of irregular 
shaped axons (Fig 14), suggesting increased axonal perturbation in 12-month-old P0het 
JHD-/- mice. 
 
Neurological deterioration and impaired muscle strength are typical features in CMT1 and 
primarily caused by demyelination and impaired axon function (Scherer and Wrabetz, 
2008; Nave, 2010). Therefore it was investigated whether the observed axonal perturbation 
(SMI32-positive axons) is reflected by and altered neurological phenotype in 12-month-old 
P0het JHD-/- mice. P0het JHD+/+ mice demonstrated significantly decreased distal and 
proximal compound muscle action potential (CMAP) amplitudes at 12 months of age (Fig. 
15A, B) and also showed slowed nerve conduction velocities (NCV) (Fig. 15C), as well as 
prolonged F-wave latencies (Fig. 15D) compared to wildtype mice, as previously reported 
(Martini et al., 1995; Zielasek et al., 1996). JHD deficiency had no significant effect on the 
investigated neurological parameters (Fig. 15). 
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Figure 14: Increased axonal perturbation in 12-month-old P0het JHD-/- mice. 
Immunohistochemistry against non-phosphorylated neurofilaments (SMI32; grayscale) and P0 
(green) in cross-sections of femoral quadriceps nerves from 12-month-old wildtype (P0wt 
JHD+/+), single (P0het JHD+/+) and double mutant mice (P0het JHD-/-). Note increased SMI32-
immunoreactivity in P0het JHD-/- mice compared to P0wt JHD+/+ and P0het JHD+/+ mice. Scale 
bar, 20µm. 
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Figure 15: Impaired physiological properties in 12-month-old P0het mutants.  A. - B. Distal 
(A) and proximal (B) compound muscle action potential (CMAP) amplitudes in 12-month-old 
mice. P0het JHD+/+ mice have significantly lowered amplitudes compared to wildtype littermates. 
JHD deficiency has no further effect on CMAP amplitudes.  C. Quantification of nerve conduction 
velocity (NCV). JHD deficiency has no effect on NCV in P0wt mice, but is significantly reduced in 
P0het JHD+/+ and P0het JHD-/- mice. D. F-wave latencies are prolonged in P0het JHD+/+ mutants 
in comparison to P0wt JHD+/+ mice. No further prolongation in the F-wave latency is detectable in 
P0het JHD-/- mice. n = 5 - 8; one-way ANOVA with Bonferroni-Holm correction; # (significant 
difference to P0wt JHD+/+), # P < 0.05; ##, P < 0.01; ###, P < 0.001.  
 
 
Consistent with the nerve conduction studies, immunohistochemical stainings against pre- 
(synaptophysin) and postsynaptic (-Bungarotoxin) markers on cross-sections of the flexor 
digitorum brevis muscle from 12-month-old mice (Fig. 16A) displayed a significant 
increase in the number of denervated and partially denervated neuromuscular junctions 
(NMJs) in P0het JHD+/+ mice compared to wildtype littermates (Fig. 16B).  P0het JHD-/- 
mice showed similarly increased values (Fig. 16B). Moreover, electron microscopic 
quantification of axon numbers and periaxonal vacuoles (readout parameters for axonal 
damage) in femoral quadriceps nerves revealed no significant alterations between P0het 
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JHD+/+ and P0het JHD-/- mice (Fig. 16C, D). Together these results suggest that P0het 
JHD-/- mice show increased histological signs of axonal perturbation in peripheral nerves 
(SMI32-positive axons) without physiological consequences when standard neurographic 
techniques were used (CMAP amplitudes). This goes along with a lack of increased 
numbers of periaxonal vacuoles and denervation of NMJs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: JHD deficiency has no impact on axonal loss and muscle denervation in 12-month-
old P0het mutants. A. Representative immunohistochemical staining of synaptophysin (Syn) and 
labeling with α-Bungarotoxin (αBTX) to detect pre- and postsynapses, respectively, at 
neuromuscular junctions (NMJ) within cross-sections of the flexor digitorum brevis muscle from 
P0het JHD-/- mice. Arrows depict completely denervated NMJs; arrowhead depicts a partially 
denervated NMJ. Scale bar, 20 µm. B. Denervated/partially denervated NMJs are significantly 
increased in P0het JHD+/+ and P0het JHD-/- mice compared to wildtype littermates. n = 4; one-
way ANOVA with Bonferroni-Holm correction; # (significant difference to P0wt JHD+/+), # P < 
0.05. C. Quantification of the number of axons in femoral quadriceps nerve cross-sections reveals 
no significant alteration between investigated groups. n = 4; one-way ANOVA; P > 0.05. D. 
Quantification of periaxonal vacuoles in femoral quadriceps nerve cross-sections. The percentage 
of periaxonal vacuoles is significantly increased in P0het JHD+/+ and P0het JHD-/- mice compared 
to wildtype littermates. n = 4 - 7; Kruskal-Wallis test with Bonferroni-Holm correction. # 
(significant difference to P0wt JHD+/+). #, P < 0.05; ##, P < 0.01. n.d. (not detected). 
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5.8. Altered numbers of immune-related cells in 12-month-old P0het JHD-/- mice 
 
In order to get more insights into the pathomechanisms that lead to aggravated nerve 
damage in P0het JHD-/- mice at 12 months of age, T-lymphocytes as possible amplifiers of 
disease progression were investigated. CD8-positive T-lymphocytes were scarcely 
detectable in peripheral nerves of P0het JHD+/+ and P0het JHD-/- mice at 12 months of 
age (not shown) and therefore not further considered to be involved in the pathogenesis. 
Quantification of CD4-positive T-lymphocytes revealed a significant difference between 
P0het JHD+/+ and P0het JHD-/- mice (Fig. 17). Whereas the number of CD4-positive T-
lymphocytes was significantly reduced in 6-month-old P0het JHD-/- mice, this number 
was significantly elevated at 12 months of age compared to P0het JHD+/+ single mutants 
(Fig. 17). This suggests that CD4-positive T-lymphocytes might contribute to the 
demyelinating phenotype in 12-month-old P0het JHD-/- mice. 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Increased number of CD4-positive T-lymphocytes in 12-month-old P0het JHD-/- 
mice. A. - B. Quantification of CD4-positive T-lymphocytes in femoral quadriceps nerve cross-
sections from 6- (A) and 12-month-old mice (B).  A. CD4-positive lymphocytes are significantly 
elevated in P0het JHD+/+ mutant mice compared to wildtype littermates, but significantly reduced 
in P0het JHD-/- mice.  B. At 12 months of age the number of CD4-positive T-lymphocytes is 
significantly elevated in P0het JHD-/- mice compared to P0het JHD+/+ and wildtype littermates. n 
= 3 - 6; Kruskal-Wallis test with Bonferroni-Holm correction, # (significant difference to P0wt 
JHD+/+), * (significant difference between P0het mutant groups). #, * P < 0.05.  For comparison, 
data from 6-month-old mice, as shown in figure 8 are presented here again. 
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As a next step, immunohistochemical stainings were performed against CD86 and CD206, 
to determine the polarization status of macrophages at 12 months of age. In femoral 
quadriceps nerve cross-sections from P0het JHD+/+ mice the number of CD86-positive 
cells increased from 6 to 12 months of age and was significantly elevated compared to 
wildtype littermates (Fig. 18A, B). In contrast to 6 months of age this number was further 
augmented in 12-month-old P0het JHD-/- mice (Fig. 18A, B). The number of CD206-
positive cells was elevated in P0het JHD+/+ mice compared to wildtype littermates at 12 
months of age but did not significantly differ between P0het JHD+/+ and P0het  JHD-/- 
mice (Fig. 18C, D). Consistent with F4/80-positive macrophage numbers (see Fig. 7 and 
Fig. 12) the number of both M1- and M2-polarized cells was not altered in cutaneous 
saphenous nerves in all genotypes at both investigated ages (Fig. 18A - D). To further 
substantiate and extend these findings, double immunohistochemistry was performed 
against CD86 and F4/80 to determine M1-polarized macrophages. Indeed, both phenotypes 
could be observed in femoral quadriceps nerves (Fig. 18.E). Most interestingly, 
macrophages with an activated, myelin-phagocytosing appearance were found either 
positive or negative for the M1 associated marker CD86 (Fig. 18E). These results suggest 
that JHD deficiency leads to a shift of macrophage polarization during disease progression 
in P0het mice and that the increased number of macrophages in P0het JHD-/- mice at 12 
months of age is preferentially due to an elevated number of CD86-positive, M1-polarized 
cells that most likely contribute to myelin degeneration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. Results 47 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Altered macrophage polarization in 6 and 12-month-old P0het JHD-/- mice. A. - B. 
Quantification of CD86-positive cells (M1) in 6- (A) and 12-month-old mice (B). A. P0het JHD+/+ 
mice show significantly increased number of CD86-positive cells compared to P0wt JHD+/+ mice 
at 6 months of age. Consistent with macrophage numbers, M1-polarized cells are significantly 
reduced in P0het JHD-/- mice compared to P0het JHD+/+ single mutants. B. In 12-month-old 
P0het JHD+/+ mice the number of CD86-positive cells is further increased. P0het JHD-/- mutants 
show further augmented numbers of CD86-positive cells. C. - D. Quantification of CD206-positive 
cells (M2) in 6- (C) and 12-month-old mice (D). No alteration in the number of CD206-positive 
cells can be detected in P0het JHD+/+ and P0het JHD-/- mice at 6 months of age (C). At 12 months 
of age the number of CD206-positive cells is significantly increased in both P0het JHD+/+ and 
P0het JHD-/- mice compared to wildtype littermates (D). n = 3 - 5; one-way ANOVA with 
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Bonferroni-Holm correction, # (significant difference to P0wt JHD+/+), * (significant difference 
between P0het mutant groups). #, * P < 0.05; ##, ** P < 0.01; ###, *** P < 0.001. For comparison, 
data from 6-month-old mice, as shown in figure 8 are presented here again. E. Representative 
micrographs of an immunohistochemical staining against M1-polarized, CD86-positive (red) and 
F4/80-positive macrophages (green) in cross-sections from 12-month-old P0het JHD-/- mice. 
Nuclei are labeled with DAPI. Note two different phenotypes of activated, myelin-phagocytosing 
macrophages in the endoneurium. M1-polarized macrophages (CD86
hi
-positive) are indicated by 
arrowheads, a possible M2-polarized macrophage (CD86
low
-positive) is indicated by an arrow. 
Scale bar = 20 µm. 
 
 
To further characterize macrophage polarization in peripheral nerves of 12-month-old 
single and double mutants, the expression of M1 and M2 associated markers as well as 
pro- and anti-inflammatory cytokines (Biswas and Mantovani, 2010; Ydens et al., 2012) 
was analyzed by semi-quantitative real-time PCR (qRT-PCR) (Fig. 19 and 20). Consistent 
with the immunohistochemical observations (Fig. 18B), CD86 mRNA expression was 
significantly increased in P0het JHD-/- mice (Fig. 19A). Interestingly, the majority of M2-
associated genes, like CD206, TREM-2, FIZZ, Ym1, and Arginase-1 were also elevated in 
their expression in P0het JHD-/- mice compared to P0het JHD+/+ single mutants and 
wildtype littermates (Fig. 19B - F). Moreover, JHD deficiency resulted also in increased 
mRNA expression of Fc receptors (Fig. 19G, H).  
 
Furthermore, an altered cytokine profile could be detected in peripheral nerves upon JHD 
deficiency. The expression of several known immune mediators, like CCL2/MCP-1, CSF-
1, LIF or IL-1 (Martini et al., 2008) was increased in P0het JHD-/- double mutants 
compared to P0het JHD+/+ single mutants and wildtype littermates (Fig. 20A - D). Of 
note, none of the characteristic M1 associated pro-inflammatory cytokines such as IL-6, 
iNOS or IFN (not detectable) were elevated in their expression in P0het JHD+/+ and 
P0het JHD-/- mice (Fig. 20E, F). TNF levels were increased both in P0het JHD+/+ and 
P0het JHD-/- mutants compared to wildtype mice (Fig. 20G). On the other hand, the 
expression of the M2 associated anti-inflammatory cytokine TGF- was significantly 
increased in P0het JHD-/- mice (Fig. 20H). Together these results suggest that JHD 
deficiency triggers an enhanced M2-polarized (alternative) macrophage response in 12-
month-old P0het mice, similar to observations after acute nerve injury (Ydens et al., 2012). 
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Figure 19: JHD deficiency triggers an M2-polarized (alternative) macrophage response in 12-
month-old P0het mice. A. - H. mRNA expression of M1 (A) and M2 (B - F) associated genes in 
femoral quadriceps nerves from 12-month-old wildtype (P0wt JHD+/+), single (P0het JHD+/+) 
and double mutant mice (P0het JHD-/-) was analyzed by qRT-PCR. mRNA expression levels are 
shown as fold induction to P0wt JHD+/+ and are all significantly increased in P0het JHD-/- mice 
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compared to P0het JHD+/+ single mutants and wildtype littermates. G. - H. mRNA expression 
levels for Fcreceptors are also significantly increased in P0het JHD-/- mice.  n = 3 - 4; mean + 
SEM (standard error of mean); one-way ANOVA with Bonferroni-Holm correction, # (significant 
difference to P0wt JHD+/+), * (significant difference between P0het mutant groups). #, * P < 0.05; 
##, ** P < 0.01; ###, *** P < 0.001. 
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Figure 20: JHD deficiency leads to an increased cytokine production in 12-month-old P0het 
mice. A. - H. The mRNA expression of immune mediators (A - D), M1 (E - G), and M2 associated 
(H) cytokines in femoral quadriceps nerves from 12-month-old wildtype (P0wt JHD+/+), single 
(P0het JHD+/+) and double mutant mice (P0het JHD-/-) was analyzed by qRT-PCR. mRNA 
expression levels are shown as fold induction to P0wt JHD+/+. Several immune mediators (A - D) 
are significantly increased in their expression in P0het JHD-/- mice compared to P0het JHD+/+ 
single mutants and wildtype littermates, whereas the expression of typical M1 associated pro-
inflammatory cytokines is not altered (E - G). H. mRNA expression of the M2 associated anti-
inflammatory cytokine TGF- is significantly increased in P0het JHD-/- mice.  n = 3 - 4; mean + 
SEM (standard error of mean); one-way ANOVA with Bonferroni-Holm correction, # (significant 
difference to P0wt JHD+/+), * (significant difference between P0het mutant groups). #, * P < 0.05; 
##, ** P < 0.01; ###, *** P < 0.001. 
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6. Discussion  
 
Several previous results highlighted the important role of secondary low grade 
inflammation - implicating macrophages and lymphocytes - as a disease amplifier in 
mouse models for primarily genetically-induced nerve disorders (Martini et al., 2013). 
However, the exact function of the adaptive immune system in the pathogenesis of 
CMT1B is not completely understood. Interestingly, a previous study demonstrated that 
endogenous antibodies - as a part of the adaptive immune system - bound to myelin 
components contribute to the activation of macrophages and rapid myelin clearance during 
Wallerian degeneration (Vargas et al., 2010). Based on these observations, the pathogenic 
impact of endogenous antibodies was investigated in peripheral nerves of a mouse model 
for CMT1B (P0het mice). 
  
 
6.1. Endogenous antibodies accumulate in peripheral nerves of P0het myelin mutant 
mice 
 
This study demonstrates for the first time that endogenous antibodies strongly accumulate 
in the endoneurium of femoral quadriceps nerves from P0het mice compared to wildtype 
littermates. By immunohistochemistry and Western blot analysis it could be shown that 
these antibodies comprise both IgG and IgM subtypes. Moreover, immunocytochemical 
investigations on single teased fiber preparations revealed that endogenous antibodies are 
associated with the extracellular domains of endoneurial tubes and also located at the 
nodes of Ranvier. Furthermore, IgG-immunoreactivity was not only detectable in 6- and 
12-month-old P0het mice, but already at 1 month of age, an early time point in disease 
before demyelinating features are morphologically visible, suggesting that endogenous 
antibodies probably contribute to early pathogenesis in an animal model for CMT1B. 
Supporting this view, the non-affected sensory branch of the femoral nerve (saphenous 
nerve) lacked this prominent antibody deposition in P0het mutant mice.  
 
Similar observations have been gained after peripheral nerve injury, where endogenous 
antibodies accumulate along endoneurial tubes of lesioned nerves (Vargas et al., 2010). Of 
note, intact nerves revealed a similarly weak labeling as in wildtype mice in this study. 
Moreover, at least a subpopulation of systemic antibodies recognized the myelin 
component P0 (MPZ) (Vargas et al., 2010). Based on the similar staining pattern and the 
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systemic presence of such antibodies even in wildtype mice, it is very likely that the 
antibodies accumulating in the endoneurium of P0het mice share the same or similar 
epitopes. Interestingly, in both P0wt and P0het mice at 6 and 12 months of age a strong 
antibody deposition was detectable in the perineurium of femoral nerves, whereas a much 
lower IgG-immunoreactivity was visible in the perineurium of 1-month-old mice. The 
relevance of this observation is enigmatic.  
 
The question emerges why endogenous, preexisting antibodies bind to myelin components 
in P0het mutants and do not accumulate in wildtype mice. It is likely that an intact blood-
nerve barrier explains the diminished antibody deposition (Bouldin et al., 1990; Vargas et 
al., 2010). Additionally, it might be possible that some epitopes are only accessible under 
pathological conditions and ‘hidden’ in normal myelin. Supporting the latter hypothesis, an 
interrupted blood-nerve barrier was not observed in young CMT1B mice (Martini, 
unpublished observations). Furthermore, previous results demonstrated the presence of 
anti-PMP22 antibodies in sera from CMT1 patients, but immunohistochemical analysis 
revealed that myelinated fibers of healthy controls were not stained when they were 
incubated with isolated anti-PMP22 IgGs (Ritz et al., 2000).  
 
Another important mediator for pattern recognition is the complement system which can be 
activated by three different pathways. Notably, antibody deposition is necessary for the 
initial activation of the classical pathway (Ramaglia et al., 2008). Previous studies 
demonstrated that the complement system exerts a similar role as antibodies in models for 
Wallerian degeneration, because its activation contributes to the efficient removal of 
myelin debris and recruitment and activation of macrophages after nerve lesion (Dailey et 
al., 1998; Ramaglia et al., 2007; Ramaglia et al., 2009). Therefore activation of the 
complement cascade might be another potential mechanism which could provide a link 
between the innate and adaptive immune system in models for CMT1. Interestingly, both 
immunocytochemistry and Western blot analysis showed no indications for the activation 
of C3, a central component in the complement system, in the disease progression of P0het 
myelin mutant mice, suggesting that an involvement in the pathogenesis is rather unlikely. 
These observations might also favor the possibility that complement deposition is related 
to axonal damage, a pathogenic feature that is rather mild in P0het mice. However, further 
crossbreeding experiments with mice that lack specific complement components are 
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necessary to determine the exact function of the complement system in the pathogenesis of 
other CMT1 mouse models in detail.  
 
 
6.2. Crucial role for endogenous antibodies in early macrophage-mediated 
demyelination  
 
In order to investigate the functional role of antibodies in a mouse model for CMT1B, 
P0het mutant mice were crossbred with JHD-deficient mice that lack B-lymphocytes, and 
therefore antibodies. In 6-month-old P0het mice, the lack of antibodies resulted in a 
reduced elevation of macrophage numbers in femoral quadriceps nerves. Furthermore, the 
demyelinating phenotype was substantially ameliorated in P0het JHD-/- mice. 
Reconstitution with murine antibodies (IgG fraction) restored antibody deposition in 
peripheral nerves and reverted the neuropathy in P0het JHD-/- mice, thereby confirming 
the potentially pathogenic role of endogenous antibodies at this stage of the disease. Of 
note, passive transfer into P0wt JHD-/- mice had no effect on macrophage activation and 
nerve structure. This implies that the deterioration after passive antibody transfer is 
dependent on the susceptibility of mutated Schwann cells in P0het mice. Corroborating this 
hypothesis, passive antibody transfer had no effect in P0wt RAG1-/- mice, but led to a 
substantial disease aggravation in P0het RAG1-/- double mutants at 8 months of age (Klein 
and Martini, unpublished observations). Taken together, these data suggest that myelin 
bound antibodies might serve as a recognition signal for activated macrophages, thereby 
directly contributing to early macrophage-mediated demyelination. A similar role was 
described for accumulating antibodies in Wallerian degeneration, as JHD-deficient mice 
showed slightly delayed macrophage recruitment, impaired phagocytic activity and 
subsequent myelin removal. In addition, passive transfer of antibodies reconstituted early 
macrophage activation and rapid myelin clearance in JHD-/- mice (Vargas et al., 2010). 
 
How might antibody deposition and macrophage-mediated demyelination be linked? A 
broad range of receptors are responsible for target recognition and the phagocytic 
activation of macrophages (Taylor et al., 2005). The best characterized among these are 
Fcreceptors for immunoglobulins and the complement receptor 3 (CR3, also known as 
CD11b) for complement component C3bi which both can act synergistically on 
macrophages (Rotshenker, 2003; Hall et al., 2006). Since complement deposition could not 
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be found along P0het mutant nerve fibers, an involvement of CR3 in the pathogenesis of 
CMT1B is unlikely. By contrast, the expression of Fcγ receptors is increased in P0het 
mutants (this study) and the receptor is also amply detectable on endoneurial macrophages 
(Klein and Martini, unpublished observation), and might therefore be an important 
mediator to link innate and adaptive immune reactions in a mouse model for CMT1B. In 
fact, the involvement of other macrophage receptors (i.e. mannose receptor, scavenger 
receptor or Toll-like receptors (TLR)) in the pathogenesis of CMT1 cannot be ruled out, 
but this needs to be investigated in future experiments. 
 
Interestingly, it has been reported that CSF-1 is involved in Fc receptor upregulation in 
peritoneal macrophages (Magee et al., 1987) and under various pathological conditions 
(Chitu and Stanley, 2006). As CSF-1 expression is increased in peripheral nerves of 
distinct CMT1 mouse models (Fischer et al., 2008b; Groh et al., 2012; Kohl and Martini, 
unpublished observations), it is conceivable that CSF-1 not only leads to intrinsic 
macrophage proliferation and activation (Müller et al., 2007), but additionally increases 
Fcreceptor expression on macrophages to prime them for subsequent recognition of 
antibody depositions. Supporting this idea, this study shows that Fcreceptor mRNA 
expression correlates with the level of CSF-1 expression in 12-month-old P0het JHD+/+ 
single and P0het JHD-/- double mutants. 
 
Surprisingly, reconstitution with antibodies specific to a non-mammalian antigen, keyhole 
limpet hemocyanin (KLH), or with murine IgG Fc-fragments resulted in an intermediate 
effect. Although antibody deposition was, as expected, not detectable in peripheral nerves, 
endoneurial macrophage numbers were elevated together with an aggravated myelin 
degeneration in individual animals in comparison to non-reconstituted P0het JHD−/− mice. 
Although the corresponding values in the reconstituted and non-reconstituted double 
mutants were not significantly different from each other, these data may suggest that not 
only myelin bound antibodies, but also systemic, ‘free’ antibodies might have the capacity 
to contribute to macrophage activation. Notably, passive transfer of unspecific anti-GFP 
antibodies also generated a mild, non-significant increase in the number of infiltrated 
macrophages in the lesion model which was not further addressed by the authors (Vargas 
et al., 2010).  
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6.3. JHD deficiency triggers increased immune reactions and disease aggravation in 
12-month-old P0het mice  
 
In previous studies it was demonstrated that the lack of T- and B-lymphocytes resulted in a 
substantial and persistent reduction of endoneurial macrophages and amelioration of the 
demyelinating phenotype in two models of CMT1 (Schmid et al., 2000; Kobsar et al., 
2003), similar to the findings of 6-month-old P0het JHD-/- mice which lack B-
lymphocytes and antibodies solely. Thus, P0het JHD-/- double mutants were also 
investigated at the age of 12 months and compared to the findings from P0het RAG1-/- 
mice. P0het single mutants showed increased numbers of macrophages compared to 6 
months of age, confirming previous results (Fischer et al., 2008b) and reflecting the 
increased inflammatory reaction during the progressive disease development. 
Unexpectedly, JHD-deficient P0het mice presented more macrophages in peripheral 
nerves, contrary to the observations at 6 months of age. Furthermore, double mutants 
revealed an aggravated demyelinating phenotype compared to P0het JHD+/+ single 
mutants. This could be a consequence of myelin-phagocytosing macrophages that were 
also amply detectable in P0het JHD-/- double mutants, corroborating the correlation 
between the total number of endoneurial macrophages and subsequent nerve fiber damage. 
These results clearly demonstrate that JHD deficiency has, in contrast to RAG1 deficiency, 
opposite effects in the disease course of P0het mice.  
 
How is target recognition in the absence of antibody and complement deposition regulated, 
and myelin phagocytosis possible in 12-month-old P0het JHD-/- mice? Despite Fc and 
complement receptor-mediated myelin removal (Kuhlmann et al., 2002; Rotshenker, 
2003), several studies demonstrated the involvement of other receptors expressed on 
macrophages/microglia under various pathological conditions, like scavenger receptor 
(Reichert and Rotshenker, 2003; Rotshenker et al., 2008; Hendrickx et al., 2013), Galectin-
3 (Rotshenker et al., 2008; Mietto et al., 2013), and Toll-like receptors (TLR) (Mietto et 
al., 2013). However, if these receptors contribute to myelin degeneration in mouse models 
for CMT1 is not known and needs to be investigated in future studies. 
  
Considering typical symptoms in CMT1 patients, axonal damage and subsequent muscular 
atrophy are crucial factors that determine the clinical outcome (Scherer and Wrabetz, 
2008). As an indicator for axonal perturbation, immunohistochemical stainings against 
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non-phosphorylated neurofilaments (SMI32) (Groh et al., 2010) were investigated in this 
study. The rather mild axonopathic phenotype in peripheral nerves of P0het mice at 12 
months of age was reflected by only slightly increased SMI32-immunoreactive profiles 
compared to wildtype littermates. Interestingly, P0het JHD-/- mice had elevated numbers 
of SMI32-positive, irregular shaped axons. This does not stringently reflect axonal 
degeneration or injury, as axon numbers and the percentage of periaxonal vacuoles were 
unchanged between P0het JHD+/+ single and P0het JHD-/- double mutants. Therefore, the 
reason for the increased number of SMI32-positive axons remains elusive.   
 
How might JHD deficiency result in these divergent effects during pathogenesis in P0het 
mutant mice? In contrast to RAG1 deficiency, T-lymphocytes are still present in JHD-
deficient mice. Of note, CD8-positive T-lymphocytes were barely detectable in peripheral 
nerves of P0het JHD+/+ and P0het JHD-/- mice at 6 and 12 months of age, and therefore 
not further considered to contribute to disease progression. Quantification of CD4-positive 
T-lymphocytes revealed significant differences between P0het JHD+/+ and P0het JHD-/- 
mice. In 6-month-old P0het JHD-/- mice the number of CD4-positive T-lymphocytes was 
substantially reduced compared to P0het JHD+/+ mice. In contrast, CD4-positive T-
lymphocytes were significantly increased at 12 months of age compared to P0het single 
mutants, thus correlating with the respective degree of demyelination. Despite the overall 
low absolute numbers, these results suggest that CD4-positive T-lymphocytes might 
contribute to the demyelinating phenotype in 12-month-old P0het JHD-/- mice. It is 
plausible to assume that T-lymphocytes might modulate the activation of macrophages 
(Mäurer et al., 2002; Ip et al., 2006). This might also explain the distinct nerve phenotype 
between JHD- and RAG1-deficient P0het mutants at 12 months of age, as the latter lack 
this potential disease-amplifying effect of T-lymphocytes.  
 
Several recent studies have demonstrated that macrophages can become polarized to pro- 
and anti-inflammatory states (Gordon, 2003; Shechter and Schwartz, 2013). These 
‘classically-activated’ (M1) or ‘alternatively activated’ (M2) macrophages possess 
different functional properties and can be either detrimental or beneficial for nervous tissue 
(Gordon, 2003; Kigerl et al., 2009; David and Kroner, 2011). To further elucidate 
differences in the inflammatory response in peripheral nerves of 12-month-old single and 
double mutants, the activation state of macrophages was investigated by 
immunohistochemistry against CD86 or CD206, typical markers for M1-polarized or M2-
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polarized macrophages, respectively (Gordon, 2003; Kigerl et al., 2009). During disease 
progression the number of CD86-positive cells increased in P0het JHD+/+ mice compared 
to wildtype littermates. Interestingly, P0het JHD-/- double mutants at 6 months of age had 
reduced numbers of M1-polarized macrophages, whereas 12-month-old P0het JHD-/- 
double mutants showed further increased numbers of CD86-positive cells. In contrast, the 
number of CD206-positive cells did not differ between P0het JHD+/+ and P0het JHD-/- 
mice and was only significantly increased compared to wildtype mice at the age of 12 
months. Consistent with macrophage numbers the number of both M1- and M2-polarized 
cells was not altered in the cutaneous saphenous nerve in all genotypes. These results 
suggest that JHD deficiency leads to a shift of macrophage polarization during disease 
development in P0het mice and that the elevated number of macrophages in P0het JHD-/- 
mice at 12 months of age is preferentially due to an increased number of CD86-positive 
cells that most likely contribute to the demyelinating phenotype. 
 
To further corroborate these findings, the expression levels of several pro- and anti-
inflammatory cytokines, as well as M1- and M2-associated genes (Biswas and Mantovani, 
2010; Ydens et al., 2012) were investigated by qRT-PCR. This was performed in order to 
elucidate the ‘inflammatory milieu’ in peripheral nerves of wildtype and mutant mice at 
the age of 12 months. The increased number of inflammatory cells in P0het JHD-/- double 
mutants compared to P0het JHD+/+ single mutants that could be detected by 
immunohistochemistry was consistent with an elevated expression of several characteristic 
immune mediators, like CCL2/MCP-1, CSF-1, LIF or IL-1 (Martini et al., 2008). 
Confirming the immunohistochemical data, CD86 mRNA expression was significantly 
increased in P0het JHD-/- compared to P0het JHD+/+ mice. However, other M1 associated 
genes, like iNOS, IL-6 or IFN, showed no elevated expression in P0het JHD+/+ and 
P0het JHD-/- mice. On the other hand, the expression of the M2 associated, anti-
inflammatory cytokine TGF-was significantly increased in P0het JHD-/- mice. 
Additionally, the expression of prototypical M2 associated genes, like TREM2, Arginase1, 
FIZZ1, CD206, and YM1, was substantially elevated in P0het JHD-/- mice compared to 
P0het JHD+/+ single mutants. Interestingly, TGF-, CCL2, and CSF-1, which are all 
increased in their expression in P0het JHD-/- mice, have been described to foster M2-
polarization in tumor associated macrophages (TAM) (Biswas and Mantovani, 2010; Van 
Overmeire et al., 2014), proposing similar mechanisms in endoneurial macrophages. It was 
also reported that Galectin-3 expression is induced in M2-polarized macrophages 
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(MacKinnon et al., 2008), again suggesting that other receptors might compensate - in the 
absence of endogenous antibodies - for target recognition and Fc receptor-mediated 
myelin removal.  
 
On the first glance, the qRT-PCR data might be in disagreement with the 
immunohistochemical observations. However, M1- and M2-activation are only ‘the 
extremes of a continuum’ (Mantovani et al., 2004). Thus, it was shown that M2b/M2-like-
polarized macrophages share the expression of some M2 associated markers, but can also 
express M1 associated genes, like CD86 (Mosser, 2003; Mantovani et al., 2004). 
Supporting this view, F4/80-positive macrophages with a myelin-phagocytosing 
appearance that are thought to be M2-polarized were also found to be positive for CD86.  
 
Taken together, JHD deficiency triggers enhanced immune reactions and an altered 
cytokine profile, as well as an M2-polarized macrophage response in 12-month-old P0het 
mice, similar to observations in Wallerian degeneration (Ydens et al., 2012). Although M2-
polarized macrophages mediate tissue repair, and are considered to be beneficial under 
various disease conditions (Gordon, 2003; Kigerl et al., 2009; Mantovani et al., 2013), they 
seem to have a detrimental function in mouse models for CMT1 disorders when they are 
chronically activated under nonlesion conditions. Presently it is difficult to decide whether 
the absence of accumulating antibodies or the altered cytokine profile due to JHD 
deficiency is responsible for the aggravated demyelinating phenotype at 12 months of age. 
Notably, another possible function of antibodies was demonstrated in distinct CNS 
disorders, as they bind to the surface of oligodendrocytes and modulate their intracellular 
signaling, thereby promoting remyelination, interestingly, in the absence of Fc function 
(Ciric et al., 2003; Warrington and Rodriguez, 2008; Wright et al., 2009). There is no 
evidence that accumulating antibodies in the PNS might exert similar effects on mutant 
Schwann cells, but it is tempting to speculate that they can also directly modulate 
intracellular signaling or cytokine expression. Supporting this hypothesis, antibody 
depositions are preferentially detectable in the femoral quadriceps as opposed to the 
saphenous nerve, as the latter lacks an increased cytokine expression (MCP-1/CCL2, CSF-
1) and is protected from inflammatory reactions and myelin degeneration.  
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6.4. The immune system as a therapeutic target for CMT1  
 
Despite the remarkable progress in CMT research in the last years, there is still no 
causative cure available for affected patients and only rehabilitative strategies or surgeries 
are available as therapeutic approaches (Schenone et al., 2011). Therefore, novel 
approaches are needed to determine beneficial therapies to treat inherited peripheral 
neuropathies. Several potential therapeutic agents demonstrated improvement in animal 
models for CMT1A, like ascorbic acid (Passage et al., 2004) or neurotrophin-3 (NT3) 
(Sahenk et al., 2005; Sahenk et al., 2014), but clinical trials failed to translate an 
unequivocal beneficial effect in humans (Pleasure and Chance, 2005; Burns et al., 2009; 
Micallef et al., 2009; Verhamme et al., 2009; Pareyson et al., 2011). 
 
To identify new therapies, disease mechanisms in preclinical animal models, that 
additionally have implications for CMT1 patients, must be determined. Considering the 
data from this study, lack of endogenous antibodies revealed beneficial effects in 6-month-
old P0het mice. Notably, endoneurial antibody deposition was also detectable in a sural 
nerve biopsy of a CMT1A patient (Klein, Sommer and Martini, unpublished observation) 
and autoantibodies were present in sera from CMT1 patients (Ritz et al., 2000), suggesting 
that B-lymphocytes and endogenous antibodies - as part of the adaptive immune system - 
might be a reasonable target for a therapeutic approach. However, JHD deficiency led to 
aggravated nerve fiber damage in 12-month-old P0het mice, arguing against this possible 
therapeutic approach. Currently it is hard to decipher whether the lack of endogenous 
antibodies or B-lymphocytes is responsible for the observed phenotype, and if they also 
possess a neuroprotective function in 12-month-old P0het JHD-/- mice. Interestingly, a 
neuroprotective role for the adaptive immune system was described in a dysmyelinating 
mutant, as RAG1-deficient P0 null double mutants showed increased axonal loss, maybe 
due to the constantly elevated numbers of potentially cytotoxic endoneurial macrophages 
(Berghoff et al., 2005).  
 
In human biopsies, prominent inflammation in peripheral nerves was reported only in some 
cases (for review see Martini and Toyka, 2004). However, some of these atypical forms of 
CMT that also presented features typical for chronic inflammatory demyelinating 
polyneuropathy (CIDP), reacted positively upon immunomodulation, like corticosteroid 
treatment (Dyck et al., 1982; Bird and Sladky, 1991; Rajabally et al., 2000; Watanabe et 
al., 2002), plasmapheresis (Malandrini et al., 1999) or intravenous immunoglobulin (IVIG) 
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treatment (Ginsberg et al., 2004; Desurkar et al., 2009; Schneider-Gold et al., 2010; Miki et 
al., 2013). It is possible that those cases that clearly show an implication of immune cells 
reflect a strong inflammatory reaction superimposed on the primarily hereditary 
demyelinating neuropathy (Martini and Toyka, 2004). Additionally, it is plausible to 
assume that macrophages were not detectable in the majority of cases, because the active 
phase of demyelination in many forms of CMT1 occurs in early pathogenesis during 
childhood (Gabreels-Festen et al., 1992; Vital et al., 1992; Garcia et al., 1998; Thomas, 
1999), when nerve biopsies are usually not performed. Supporting this hypothesis, aged 
mice (24-month-old) display also reduced numbers of macrophages in distinct CMT1 
mutants (Klein and Martini, unpublished observations), but this requires further 
investigations.  
 
Nevertheless, immunomodulation appears as a suitable therapeutic approach to treat 
CMT1. Tacrolimus (FK506) is frequently used as an immunosuppressant in patients 
receiving organ transplantations. Moreover, neuroprotective effects were described in 
various disease models (Sulaiman et al., 2002; Gold et al., 2004). However, treatment of 
P0het mice with FK506 did not reduce the number of endoneurial CD8-positive T-
lymphocytes and led to an aggravated demyelinating phenotype, excluding the drug for the 
treatment of CMT1 patients (Ip et al., 2009). 
 
Taking these observations into account, directly targeting the innate immune system might 
be a more promising approach to reduce nerve fiber damage, as myelin degeneration is 
more efficiently blocked by the absence of macrophage-activating cytokines, like 
CCL2/MCP-1 or CSF-1 (Carenini et al., 2001; Fischer et al., 2008b). Moreover, the 
adaptive immune system seems not to be pathogenetically relevant in PMP22tg mice, a 
model for CMT1A which represent the most common form of CMT1 (Kohl et al., 2010b). 
Especially CSF-1, a crucial mediator in macrophage activation, has a substantial role in 
disease progression as shown by genetic ablation in three CMT1 mouse models (Carenini 
et al., 2001; Groh et al., 2012; Groh and Martini, unpublished observations). Activation of 
macrophages by CSF-1-producing fibroblasts was also recently observed in nerve biopsies 
of distinct CMT1 patients (Groh et al., 2012). CSF-1 signaling has additionally been shown 
to be involved in Fc receptor upregulation in murine peritoneal macrophages (Magee et al., 
1987), suggesting that blocking this pathway might be a promising therapeutic approach to 
reduce neuroinflammation and subsequent nerve damage in patients. Indeed, in a 
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preclinical experiment, mice that were treated with a highly selective CSF-1 receptor 
(CSF-1R) inhibitor (provided by Plexxikon Inc.) showed a robust decline in nerve 
macrophages. Moreover, the systemic inhibition of the CSF-1R resulted in a substantial 
reduction of typical histopathological features, and also functional improvement (Klein and 
Martini, unpublished observations), offering a clinically highly relevant and potent 
treatment option for CMT1 neuropathies.  
 
 
6.5. Synopsis 
 
In summary, this study extends the understanding about pathomechanisms in inherited 
neuropathies. Moreover, it demonstrates that endogenous antibodies contribute to initial 
mechanisms in macrophage-mediated demyelination in a mouse model for CMT1B. 
Furthermore, this study identifies endogenous antibodies as a possible link in the 
interaction between the innate and adaptive immune system in P0het mutant mice (Fig. 
21). Antibodies have also been shown to contribute to macrophage activation and rapid 
myelin clearance after peripheral nerve lesion. Therefore, this study supports the view that 
CMT1 disorders and Wallerian degeneration share common pathomechanisms that are 
beneficial after nerve injury, but detrimental under nonlesion conditions.  
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Figure 21: Synoptic view on the proposed pathomechanisms in P0het mice. Important 
mediators are hierarchically represented by their size in the scheme. In wildtype mice (P0wt, left) 
myelinating Schwann cells (SC) show only mild deposition of endogenous antibodies. Nerve 
resident fibroblasts (Fi) and macrophages (M) are not activated. In CMT1B myelin mutant mice 
(P0het, right), impaired SC display an elevated expression of several pathogenic cytokines. 
Upregulation of the chemokine CCL2/MCP-1 fosters the recruitment of macrophages/monocytes 
from the circulation, thereby contributing to an increase in numbers of endoneurial macrophages. 
In contrast, fibroblasts become activated by a (possible) Schwann cell derived, so far unknown, 
cytokine to trigger subsequent expression of CSF-1. Increased CSF-1 levels lead to proliferation 
and activation of endoneurial macrophages. Moreover, a CSF-1 dependent upregulation of Fc 
receptors on macrophages facilitates the recognition of antibody depositions at the outer aspects of 
Schwann cells, leading to myelin phagocytosis and demyelination. Additionally, macrophages can 
be modulated by T-lymphocytes. However, activation of fibroblasts and subsequent CSF-1-
dependent activation of macrophages are thought to act as the major disease amplifier in the 
pathogenesis of a mouse model for CMT1B.  
 
 
7. References 64 
7. References 
 
Anzini P, Neuberg DH, Schachner M, Nelles E, Willecke K, Zielasek J, Toyka KV, Suter 
U, Martini R (1997) Structural abnormalities and deficient maintenance of 
peripheral nerve myelin in mice lacking the gap junction protein connexin 32. J 
Neurosci 17:4545-4551. 
 
Berghoff M, Samsam M, Muller M, Kobsar I, Toyka KV, Kiefer R, Maurer M, Martini R 
(2005) Neuroprotective effect of the immune system in a mouse model of severe 
dysmyelinating hereditary neuropathy: enhanced axonal degeneration following 
disruption of the RAG-1 gene. Mol Cell Neurosci 28:118-127. 
 
Bird SJ, Sladky JT (1991) Corticosteroid-responsive dominantly inherited neuropathy in 
childhood. Neurology 41:437-439. 
 
Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte 
subsets: cancer as a paradigm. Nat Immunol 11:889-896. 
 
Bouldin TW, Earnhardt TS, Goines ND (1990) Sequential changes in the permeability of 
the blood-nerve barrier over the course of ricin neuronopathy in the rat. 
Neurotoxicology 11:23-34. 
 
Brennan KM, Bai Y, Shy ME (2015) Demyelinating CMT-what's known, what's new and 
what's in store? Neurosci Lett 596:14-26.  
 
Burns J, Ouvrier RA, Yiu EM, Joseph PD, Kornberg AJ, Fahey MC, Ryan MM (2009) 
Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, 
double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 8:537-
544. 
 
Carenini S, Maurer M, Werner A, Blazyca H, Toyka KV, Schmid CD, Raivich G, Martini 
R (2001) The role of macrophages in demyelinating peripheral nervous system of 
mice heterozygously deficient in p0. J Cell Biol 152:301-308. 
 
Casasnovas C, Cano LM, Alberti A, Cespedes M, Rigo G (2008) Charcot-Marie-tooth 
disease. Foot Ankle Spec 1:350-354. 
 
Chen J, Trounstine M, Kurahara C, Young F, Kuo CC, Xu Y, Loring JF, Alt FW, Huszar 
D (1993) B cell development in mice that lack one or both immunoglobulin kappa 
light chain genes. Embo J 12:821-830. 
 
Chitu V, Stanley ER (2006) Colony-stimulating factor-1 in immunity and inflammation. 
Curr Opin Immunol 18:39-48. 
 
Ciric B, Howe CL, Paz Soldan M, Warrington AE, Bieber AJ, Van Keulen V, Rodriguez 
M, Pease LR (2003) Human monoclonal IgM antibody promotes CNS myelin 
repair independent of Fc function. Brain Pathol 13:608-616. 
 
7. References 65 
Dailey AT, Avellino AM, Benthem L, Silver J, Kliot M (1998) Complement depletion 
reduces macrophage infiltration and activation during Wallerian degeneration and 
axonal regeneration. J Neurosci 18:6713-6722. 
 
David S, Kroner A (2011) Repertoire of microglial and macrophage responses after spinal 
cord injury. Nat Rev Neurosci 12:388-399. 
 
Desurkar A, Lin JP, Mills K, Al-Sarraj S, Jan W, Jungbluth H, Wraige E (2009) Charcot-
Marie-Tooth (CMT) disease 1A with superimposed inflammatory polyneuropathy 
in children. Neuropediatrics 40:85-88. 
 
Dyck PJ, Swanson CJ, Low PA, Bartleson JD, Lambert EH (1982) Prednisone-responsive 
hereditary motor and sensory neuropathy. Mayo Clin Proc 57:239-246. 
 
Fischer S, Weishaupt A, Troppmair J, Martini R (2008a) Increase of MCP-1 (CCL2) in 
myelin mutant Schwann cells is mediated by MEK-ERK signaling pathway. Glia 
56:836-843. 
 
Fischer S, Kleinschnitz C, Muller M, Kobsar I, Ip CW, Rollins B, Martini R (2008b) 
Monocyte chemoattractant protein-1 is a pathogenic component in a model for a 
hereditary peripheral neuropathy. Mol Cell Neurosci 37:359-366. 
 
Fledrich R, Stassart RM, Sereda MW (2012) Murine therapeutic models for Charcot-
Marie-Tooth (CMT) disease. Br Med Bull 102:89-113. 
 
Gabreels-Festen AA, Joosten EM, Gabreels FJ, Jennekens FG, Janssen-van Kempen TW 
(1992) Early morphological features in dominantly inherited demyelinating motor 
and sensory neuropathy (HMSN type I). J Neurol Sci 107:145-154. 
 
Gabreels-Festen AA, Hoogendijk JE, Meijerink PH, Gabreels FJ, Bolhuis PA, van 
Beersum S, Kulkens T, Nelis E, Jennekens FG, de Visser M, van Engelen BG, Van 
Broeckhoven C, Mariman EC (1996) Two divergent types of nerve pathology in 
patients with different P0 mutations in Charcot-Marie-Tooth disease. Neurology 
47:761-765. 
 
Garcia A, Combarros O, Calleja J, Berciano J (1998) Charcot-Marie-Tooth disease type 
1A with 17p duplication in infancy and early childhood: a longitudinal clinical and 
electrophysiologic study. Neurology 50:1061-1067. 
 
Giese KP, Martini R, Lemke G, Soriano P, Schachner M (1992) Mouse P0 gene disruption 
leads to hypomyelination, abnormal expression of recognition molecules, and 
degeneration of myelin and axons. Cell 71:565-576. 
 
Ginsberg L, Malik O, Kenton AR, Sharp D, Muddle JR, Davis MB, Winer JB, Orrell RW, 
King RH (2004) Coexistent hereditary and inflammatory neuropathy. Brain 
127:193-202. 
 
Gold BG, Voda J, Yu X, Gordon H (2004) The immunosuppressant FK506 elicits a 
neuronal heat shock response and protects against acrylamide neuropathy. Exp 
Neurol 187:160-170. 
7. References 66 
Goodyear CS, O'Hanlon GM, Plomp JJ, Wagner ER, Morrison I, Veitch J, Cochrane L, 
Bullens RW, Molenaar PC, Conner J, Willison HJ (1999) Monoclonal antibodies 
raised against Guillain-Barre syndrome-associated Campylobacter jejuni 
lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve 
preparations. J Clin Invest 104:697-708. 
 
Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:23-35. 
 
Groh J, Weis J, Zieger H, Stanley ER, Heuer H, Martini R (2012) Colony-stimulating 
factor-1 mediates macrophage-related neural damage in a model for Charcot-
Marie-Tooth disease type 1X. Brain 135:88-104. 
 
Groh J, Klein I, Hollmann C, Wettmarshausen J, Klein D, Martini R (2015) CSF-1-
activated macrophages are target-directed and essential mediators of schwann cell 
dedifferentiation and dysfunction in Cx32-deficient mice. Glia 63:977-988. 
 
Groh J, Heinl K, Kohl B, Wessig C, Greeske J, Fischer S, Martini R (2010) Attenuation of 
MCP-1/CCL2 expression ameliorates neuropathy in a mouse model for Charcot-
Marie-Tooth 1X. Hum Mol Genet 19:3530-3543. 
 
Guenard V, Montag D, Schachner M, Martini R (1996) Onion bulb cells in mice deficient 
for myelin genes share molecular properties with immature, differentiated non-
myelinating, and denervated Schwann cells. Glia 18:27-38. 
 
Hall AB, Gakidis MA, Glogauer M, Wilsbacher JL, Gao S, Swat W, Brugge JS (2006) 
Requirements for Vav guanine nucleotide exchange factors and Rho GTPases in 
FcgammaR- and complement-mediated phagocytosis. Immunity 24:305-316. 
 
Hayasaka K, Takada G, Ionasescu VV (1993a) Mutation of the myelin P0 gene in Charcot-
Marie-Tooth neuropathy type 1B. Hum Mol Genet 2:1369-1372. 
 
Hayasaka K, Ohnishi A, Takada G, Fukushima Y, Murai Y (1993b) Mutation of the 
myelin P0 gene in Charcot-Marie-tooth neuropathy type 1. Biochem Biophys Res 
Commun 194:1317-1322. 
 
Hayasaka K, Himoro M, Sato W, Takada G, Uyemura K, Shimizu N, Bird TD, Conneally 
PM, Chance PF (1993c) Charcot-Marie-Tooth neuropathy type 1B is associated 
with mutations of the myelin P0 gene. Nat Genet 5:31-34. 
 
Hendrickx DA, Koning N, Schuurman KG, van Strien ME, van Eden CG, Hamann J, 
Huitinga I (2013) Selective upregulation of scavenger receptors in and around 
demyelinating areas in multiple sclerosis. J Neuropathol Exp Neurol 72:106-118. 
 
Himoro M, Yoshikawa H, Matsui T, Mitsui Y, Takahashi M, Kaido M, Nishimura T, 
Sawaishi Y, Takada G, Hayasaka K (1993) New mutation of the myelin P0 gene in 
a pedigree of Charcot-Marie-Tooth neuropathy 1. Biochem Mol Biol Int 31:169-
173. 
 
Huxley C, Passage E, Manson A, Putzu G, Figarella-Branger D, Pellissier JF, Fontes M 
(1996) Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by 
pronuclear injection of human YAC DNA. Hum Mol Genet 5:563-569. 
7. References 67 
Huxley C, Passage E, Robertson AM, Youl B, Huston S, Manson A, Saberan-Djoniedi D, 
Figarella-Branger D, Pellissier JF, Thomas PK, Fontes M (1998) Correlation 
between varying levels of PMP22 expression and the degree of demyelination and 
reduction in nerve conduction velocity in transgenic mice. Hum Mol Genet 7:449-
458. 
 
Ip CW, Kroner A, Kohl B, Wessig C, Martini R (2009) Tacrolimus (FK506) causes disease 
aggravation in models for inherited peripheral myelinopathies. Neurobiol Dis 
33:207-212. 
 
Ip CW, Kroner A, Fischer S, Berghoff M, Kobsar I, Maurer M, Martini R (2006) Role of 
immune cells in animal models for inherited peripheral neuropathies. 
Neuromolecular Med 8:175-190. 
 
Jerath NU, Shy ME (2015) Hereditary motor and sensory neuropathies: Understanding 
molecular pathogenesis could lead to future treatment strategies. Biochim Biophys 
Acta 1852:667-678. 
 
Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG (2009) 
Identification of two distinct macrophage subsets with divergent effects causing 
either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 
29:13435-13444. 
 
Klein D, Groh J, Wettmarshausen J, Martini R (2014) Nonuniform molecular features of 
myelinating Schwann cells in models for CMT1: Distinct disease patterns are 
associated with NCAM and c-Jun upregulation. Glia 62:736-750. 
 
Klein D, Groh J, Weishaupt A, Martini R (2015) Endogenous antibodies contribute to 
macrophage-mediated demyelination in a mouse model for CMT1B. J 
Neuroinflammation 12:267. 
 
Kleopa KA, Scherer SS (2006) Molecular genetics of X-linked Charcot-Marie-Tooth 
disease. Neuromolecular Med 8:107-122. 
 
Kobsar I, Maurer M, Ott T, Martini R (2002) Macrophage-related demyelination in 
peripheral nerves of mice deficient in the gap junction protein connexin 32. 
Neurosci Lett 320:17-20. 
 
Kobsar I, Hasenpusch-Theil K, Wessig C, Muller HW, Martini R (2005) Evidence for 
macrophage-mediated myelin disruption in an animal model for Charcot-Marie-
Tooth neuropathy type 1A. J Neurosci Res 81:857-864. 
 
Kobsar I, Oetke C, Kroner A, Wessig C, Crocker P, Martini R (2006) Attenuated 
demyelination in the absence of the macrophage-restricted adhesion molecule 
sialoadhesin (Siglec-1) in mice heterozygously deficient in P0. Mol Cell Neurosci 
31:685-691. 
 
Kobsar I, Berghoff M, Samsam M, Wessig C, Maurer M, Toyka KV, Martini R (2003) 
Preserved myelin integrity and reduced axonopathy in connexin32-deficient mice 
lacking the recombination activating gene-1. Brain 126:804-813. 
7. References 68 
Kohl B, Fischer S, Groh J, Wessig C, Martini R (2010a) MCP-1/CCL2 modifies axon 
properties in a PMP22-overexpressing mouse model for Charcot-Marie-tooth 1A 
neuropathy. Am J Pathol 176:1390-1399. 
 
Kohl B, Groh J, Wessig C, Wiendl H, Kroner A, Martini R (2010b) Lack of evidence for a 
pathogenic role of T-lymphocytes in an animal model for Charcot-Marie-Tooth 
disease 1A. Neurobiol Dis 38:78-84. 
 
Kroner A, Schwab N, Ip CW, Sommer C, Wessig C, Wiendl H, Martini R (2009) The co-
inhibitory molecule PD-1 modulates disease severity in a model for an inherited, 
demyelinating neuropathy. Neurobiol Dis 33:96-103. 
 
Kuhlmann T, Wendling U, Nolte C, Zipp F, Maruschak B, Stadelmann C, Siebert H, Bruck 
W (2002) Differential regulation of myelin phagocytosis by 
macrophages/microglia, involvement of target myelin, Fc receptors and activation 
by intravenous immunoglobulins. J Neurosci Res 67:185-190. 
 
Kulkens T, Bolhuis PA, Wolterman RA, Kemp S, te Nijenhuis S, Valentijn LJ, Hensels 
GW, Jennekens FG, de Visser M, Hoogendijk JE, et al. (1993) Deletion of the 
serine 34 codon from the major peripheral myelin protein P0 gene in Charcot-
Marie-Tooth disease type 1B. Nat Genet 5:35-39. 
 
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature 227:680-685. 
 
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the 
Folin phenol reagent. J Biol Chem 193:265-275. 
 
MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, 
Nilsson UJ, Haslett C, Forbes SJ, Sethi T (2008) Regulation of alternative 
macrophage activation by galectin-3. J Immunol 180:2650-2658. 
 
Magee DM, Wing EJ, Ampel NM, Waheed A, Shadduck RK (1987) Macrophage colony-
stimulating factor enhances the expression of Fc receptors on murine peritoneal 
macrophages. Immunology 62:373-378. 
 
Malandrini A, Villanova M, Dotti MT, Federico A (1999) Acute inflammatory neuropathy 
in Charcot-Marie-Tooth disease. Neurology 52:859-861. 
 
Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M (2013) Macrophage plasticity 
and polarization in tissue repair and remodelling. J Pathol 229:176-185. 
 
Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M (2004) The chemokine 
system in diverse forms of macrophage activation and polarization. Trends 
Immunol 25:677-686. 
 
Martini R (1997) Animal models for inherited peripheral neuropathies. J Anat 191 ( Pt 
3):321-336. 
 
Martini R (2001) The effect of myelinating Schwann cells on axons. Muscle Nerve 24:456-
466. 
7. References 69 
Martini R, Toyka KV (2004) Immune-mediated components of hereditary demyelinating 
neuropathies: lessons from animal models and patients. Lancet Neurol 3:457-465. 
 
Martini R, Klein D, Groh J (2013) Similarities between inherited demyelinating 
neuropathies and Wallerian degeneration: an old repair program may cause myelin 
and axon perturbation under nonlesion conditions. Am J Pathol 183:655-660. 
 
Martini R, Fischer S, Lopez-Vales R, David S (2008) Interactions between Schwann cells 
and macrophages in injury and inherited demyelinating disease. Glia 56:1566-1577. 
 
Martini R, Zielasek J, Toyka KV, Giese KP, Schachner M (1995) Protein zero (P0)-
deficient mice show myelin degeneration in peripheral nerves characteristic of 
inherited human neuropathies. Nat Genet 11:281-286. 
 
Mäurer M, Kobsar I, Berghoff M, Schmid CD, Carenini S, Martini R (2002) Role of 
immune cells in animal models for inherited neuropathies: facts and visions. J Anat 
200:405-414. 
 
Mäurer M, Schmid CD, Bootz F, Zielasek J, Toyka KV, Oehen S, Martini R (2001) Bone 
marrow transfer from wild-type mice reverts the beneficial effect of genetically 
mediated immune deficiency in myelin mutants. Mol Cell Neurosci 17:1094-1101. 
 
Mauri C, Bosma A (2012) Immune regulatory function of B cells. Annu Rev Immunol 
30:221-241. 
 
Micallef J et al. (2009) Effect of ascorbic acid in patients with Charcot-Marie-Tooth 
disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. 
Lancet Neurol 8:1103-1110. 
 
Mietto BS, Jurgensen S, Alves L, Pecli C, Narciso MS, Assuncao-Miranda I, Villa-Verde 
DM, de Souza Lima FR, de Menezes JR, Benjamim CF, Bozza MT, Martinez AM 
(2013) Lack of galectin-3 speeds Wallerian degeneration by altering TLR and pro-
inflammatory cytokine expressions in injured sciatic nerve. Eur J Neurosci 
37:1682-1690. 
 
Miki Y, Tomiyama M, Haga R, Nishijima H, Suzuki C, Kurihara A, Sugimoto K, 
Hashiguchi A, Takashima H, Baba M (2013) A family with IVIg-responsive 
Charcot-Marie-Tooth disease. J Neurol 260:1147-1151. 
 
Mombaerts P, Iacomini J, Johnson RS, Herrup K, Tonegawa S, Papaioannou VE (1992) 
RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68:869-877. 
 
Mosser DM (2003) The many faces of macrophage activation. J Leukoc Biol 73:209-212. 
 
Müller M, Berghoff M, Kobsar I, Kiefer R, Martini R (2007) Macrophage colony 
stimulating factor is a crucial factor for the intrinsic macrophage response in mice 
heterozygously deficient for the myelin protein P0. Exp Neurol 203:55-62. 
 
Nave KA (2010) Myelination and the trophic support of long axons. Nat Rev Neurosci 
11:275-283. 
7. References 70 
Nelis E, Timmerman V, De Jonghe P, Muylle L, Martin JJ, Van Broeckhoven C (1994) 
Linkage and mutation analysis in an extended family with Charcot-Marie-Tooth 
disease type 1B. J Med Genet 31:811-815. 
 
Oetke C, Vinson MC, Jones C, Crocker PR (2006) Sialoadhesin-deficient mice exhibit 
subtle changes in B- and T-cell populations and reduced immunoglobulin M levels. 
Mol Cell Biol 26:1549-1557. 
 
Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Vita G, 
Quattrone A, Padua L, Gemignani F, Visioli F, Laura M, Radice D, Calabrese D, 
Hughes RA, Solari A (2011) Ascorbic acid in Charcot-Marie-Tooth disease type 
1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet 
Neurol 10:320-328. 
 
Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, 
Robaglia-Schlupp A, Pellissier JF, Fontes M (2004) Ascorbic acid treatment 
corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 
10:396-401. 
 
Patzko A, Shy ME (2011) Update on Charcot-Marie-Tooth disease. Curr Neurol Neurosci 
Rep 11:78-88. 
 
Philpott KL, Viney JL, Kay G, Rastan S, Gardiner EM, Chae S, Hayday AC, Owen MJ 
(1992) Lymphoid development in mice congenitally lacking T cell receptor alpha 
beta-expressing cells. Science 256:1448-1452. 
 
Pleasure DE, Chance PF (2005) Neurotrophin-3 therapy for Charcot-Marie-Tooth disease 
type 1A. Neurology 65:662-663. 
 
Rajabally Y, Vital A, Ferrer X, Vital C, Julien J, Latour P, Vandenberghe A, Lagueny A 
(2000) Chronic inflammatory demyelinating polyneuropathy caused by HIV 
infection in a patient with asymptomatic CMT 1A. J Peripher Nerv Syst 5:158-162. 
 
Ramaglia V, Daha MR, Baas F (2008) The complement system in the peripheral nerve: 
friend or foe? Mol Immunol 45:3865-3877. 
 
Ramaglia V, King RH, Morgan BP, Baas F (2009) Deficiency of the complement regulator 
CD59a exacerbates Wallerian degeneration. Mol Immunol 46:1892-1896. 
 
Ramaglia V, King RH, Nourallah M, Wolterman R, de Jonge R, Ramkema M, Vigar MA, 
van der Wetering S, Morgan BP, Troost D, Baas F (2007) The membrane attack 
complex of the complement system is essential for rapid Wallerian degeneration. J 
Neurosci 27:7663-7672. 
 
Reichert F, Rotshenker S (2003) Complement-receptor-3 and scavenger-receptor-AI/II 
mediated myelin phagocytosis in microglia and macrophages. Neurobiol Dis 12:65-
72. 
 
Reilly MM, Shy ME (2009) Diagnosis and new treatments in genetic neuropathies. J 
Neurol Neurosurg Psychiatry 80:1304-1314. 
7. References 71 
Reilly MM, Murphy SM, Laura M (2011) Charcot-Marie-Tooth disease. J Peripher Nerv 
Syst 16:1-14. 
 
Ritz MF, Lechner-Scott J, Scott RJ, Fuhr P, Malik N, Erne B, Taylor V, Suter U, Schaeren-
Wiemers N, Steck AJ (2000) Characterisation of autoantibodies to peripheral 
myelin protein 22 in patients with hereditary and acquired neuropathies. J 
Neuroimmunol 104:155-163. 
 
Rotshenker S (2003) Microglia and macrophage activation and the regulation of 
complement-receptor-3 (CR3/MAC-1)-mediated myelin phagocytosis in injury and 
disease. J Mol Neurosci 21:65-72. 
 
Rotshenker S, Reichert F, Gitik M, Haklai R, Elad-Sfadia G, Kloog Y (2008) Galectin-
3/MAC-2, Ras and PI3K activate complement receptor-3 and scavenger receptor-
AI/II mediated myelin phagocytosis in microglia. Glia 56:1607-1613. 
 
Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum JM, 
Mendell JR (2005) NT-3 promotes nerve regeneration and sensory improvement in 
CMT1A mouse models and in patients. Neurology 65:681-689. 
 
Sahenk Z, Galloway G, Clark KR, Malik V, Rodino-Klapac LR, Kaspar BK, Chen L, 
Braganza C, Montgomery C, Mendell JR (2014) AAV1.NT-3 gene therapy for 
charcot-marie-tooth neuropathy. Mol Ther 22:511-521. 
 
Saporta MA, Shy ME (2013) Inherited peripheral neuropathies. Neurol Clin 31:597-619. 
 
Schenone A, Nobbio L, Monti Bragadin M, Ursino G, Grandis M (2011) Inherited 
neuropathies. Curr Treat Options Neurol 13:160-179. 
 
Scherer SS, Wrabetz L (2008) Molecular mechanisms of inherited demyelinating 
neuropathies. Glia 56:1578-1589. 
 
Scherer SS, Xu YT, Nelles E, Fischbeck K, Willecke K, Bone LJ (1998) Connexin32-null 
mice develop demyelinating peripheral neuropathy. Glia 24:8-20. 
 
Schmid CD, Stienekemeier M, Oehen S, Bootz F, Zielasek J, Gold R, Toyka KV, 
Schachner M, Martini R (2000) Immune deficiency in mouse models for inherited 
peripheral neuropathies leads to improved myelin maintenance. J Neurosci 20:729-
735. 
 
Schneider-Gold C, Kotting J, Epplen JT, Gold R, Gerding WM (2010) Unusual Charcot-
Marie-Tooth phenotype due to a mutation within the intracellular domain of myelin 
protein zero. Muscle Nerve 41:550-554. 
 
Sereda M, Griffiths I, Puhlhofer A, Stewart H, Rossner MJ, Zimmerman F, Magyar JP, 
Schneider A, Hund E, Meinck HM, Suter U, Nave KA (1996) A transgenic rat 
model of Charcot-Marie-Tooth disease. Neuron 16:1049-1060. 
 
Shechter R, Schwartz M (2013) Harnessing monocyte-derived macrophages to control 
central nervous system pathologies: no longer 'if' but 'how'. J Pathol 229:332-346. 
 
7. References 72 
Shy ME, Patzko A (2011) Axonal Charcot-Marie-Tooth disease. Curr Opin Neurol 24:475-
483. 
 
Shy ME, Arroyo E, Sladky J, Menichella D, Jiang H, Xu W, Kamholz J, Scherer SS (1997) 
Heterozygous P0 knockout mice develop a peripheral neuropathy that resembles 
chronic inflammatory demyelinating polyneuropathy (CIDP). J Neuropathol Exp 
Neurol 56:811-821. 
 
Shy ME, Jani A, Krajewski K, Grandis M, Lewis RA, Li J, Shy RR, Balsamo J, Lilien J, 
Garbern JY, Kamholz J (2004) Phenotypic clustering in MPZ mutations. Brain 
127:371-384. 
 
Sulaiman OA, Voda J, Gold BG, Gordon T (2002) FK506 increases peripheral nerve 
regeneration after chronic axotomy but not after chronic schwann cell denervation. 
Exp Neurol 175:127-137. 
 
Suter U, Scherer SS (2003) Disease mechanisms in inherited neuropathies. Nat Rev 
Neurosci 4:714-726. 
 
Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S (2005) 
Macrophage receptors and immune recognition. Annu Rev Immunol 23:901-944. 
 
Thomas PK (1999) Overview of Charcot-Marie-Tooth disease type 1A. Ann N Y Acad Sci 
883:1-5. 
 
Timmerman V, Strickland AV, Zuchner S (2014) Genetics of Charcot-Marie-Tooth (CMT) 
Disease within the Frame of the Human Genome Project Success. Genes (Basel) 
5:13-32. 
 
Van Overmeire E, Laoui D, Keirsse J, Van Ginderachter JA, Sarukhan A (2014) 
Mechanisms driving macrophage diversity and specialization in distinct tumor 
microenvironments and parallelisms with other tissues. Front Immunol 5:127. 
 
Vargas ME, Watanabe J, Singh SJ, Robinson WH, Barres BA (2010) Endogenous 
antibodies promote rapid myelin clearance and effective axon regeneration after 
nerve injury. Proc Natl Acad Sci U S A 107:11993-11998. 
 
Verhamme C, de Haan RJ, Vermeulen M, Baas F, de Visser M, van Schaik IN (2009) Oral 
high dose ascorbic acid treatment for one year in young CMT1A patients: a 
randomised, double-blind, placebo-controlled phase II trial. BMC Med 7:70. 
 
Vital A, Vital C, Julien J, Fontan D (1992) Occurrence of active demyelinating lesions in 
children with hereditary motor and sensory neuropathy (HMSN) type I. Acta 
Neuropathol 84:433-436. 
 
Warrington AE, Rodriguez M (2008) Remyelination-promoting human IgMs: developing a 
therapeutic reagent for demyelinating disease. Curr Top Microbiol Immunol 
318:213-239. 
 
7. References 73 
Watanabe M, Yamamoto N, Ohkoshi N, Nagata H, Kohno Y, Hayashi A, Tamaoka A, 
Shoji S (2002) Corticosteroid- responsive asymmetric neuropathy with a myelin 
protein zero gene mutation. Neurology 59:767-769. 
 
Williams LL, Shannon BT, Wright FS (1993) Circulating cytotoxic immune components 
in dominant Charcot-Marie-Tooth syndrome. J Clin Immunol 13:389-396. 
 
Williams LL, Shannon BT, O'Dougherty M, Wright FS (1987) Activated T cells in type I 
Charcot-Marie-Tooth disease: evidence for immunologic heterogeneity. J 
Neuroimmunol 16:317-330. 
 
Willison HJ, Goodyear CS (2013) Glycolipid antigens and autoantibodies in autoimmune 
neuropathies. Trends in immunology 34:453-459. 
 
Willison HJ, Halstead SK, Beveridge E, Zitman FM, Greenshields KN, Morgan BP, Plomp 
JJ (2008) The role of complement and complement regulators in mediating motor 
nerve terminal injury in murine models of Guillain-Barre syndrome. J 
Neuroimmunol 201-202:172-182. 
 
Wrabetz L, D'Antonio M, Pennuto M, Dati G, Tinelli E, Fratta P, Previtali S, Imperiale D, 
Zielasek J, Toyka K, Avila RL, Kirschner DA, Messing A, Feltri ML, Quattrini A 
(2006) Different intracellular pathomechanisms produce diverse Myelin Protein 
Zero neuropathies in transgenic mice. J Neurosci 26:2358-2368. 
 
Wright BR, Warrington AE, Edberg DD, Rodriguez M (2009) Cellular mechanisms of 
central nervous system repair by natural autoreactive monoclonal antibodies. Arch 
Neurol 66:1456-1459. 
 
Ydens E, Cauwels A, Asselbergh B, Goethals S, Peeraer L, Lornet G, Almeida-Souza L, 
Van Ginderachter JA, Timmerman V, Janssens S (2012) Acute injury in the 
peripheral nervous system triggers an alternative macrophage response. J 
Neuroinflammation 9:176. 
 
Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz 
LD (1990) The murine mutation osteopetrosis is in the coding region of the 
macrophage colony stimulating factor gene. Nature 345:442-444. 
 
Yuki N, Hartung HP (2012) Guillain-Barre syndrome. N Engl J Med 366:2294-2304. 
 
Zielasek J, Martini R, Toyka KV (1996) Functional abnormalities in P0-deficient mice 
resemble human hereditary neuropathies linked to P0 gene mutations. Muscle 
Nerve 19:946-952. 
 
 
 
 
8. Appendices 74 
8. Appendices 
 
8.1. Technical equipment 
 
BioPhotometer 6131  Eppendorf (Hamburg, Germany) 
Biosphere Filter Tips  Sarstedt (Nuernbrecht, Germany) 
Centrifuges  
     Biofuge 15R  Heraeus (Hanau, Germany) 
     Biofuge Pico Heraeus (Hanau, Germany) 
     Centrifuge 5424  Eppendorf (Hamburg, Germany) 
Cryostat CM 3050S  Leica (Wetzlar, Germany) 
Dry block thermostat TDB-120  Hartenstein (Wuerzburg, Germany) 
Dry block thermostat TDB-100  Hartenstein (Wuerzburg, Germany) 
ELISA reader Original Multiskan  EX Labsystems (Helsinki, Finland) 
Freezer  Liebherr (Biberach, Germany) 
Gel chambers  
     Horizontal Mini Gel System Peqlab (Erlangen, Germany) 
     Mini-PROTEAN3
®
 cell   Bio-Rad (Munich, Germany) 
     Mini-Trans-Blot
®
 cell Bio-Rad (Munich, Germany) 
Gel imager Intas (Goettingen, Germany) 
Heating plate Medax (Neumuenster, Germany) 
Homogenizer MICCRA D-8  ART (Muehlheim, Germany) 
Hyperfilm ECL GE Healthcare (Backinghamshire, UK) 
MicroAmp
® 
Fast 96-well reaction plate Applied Biosystems (Darmstadt, Germany) 
Microscopes  
     Axiophot 2  Zeiss (Oberkochen, Germany)     
     FluoView FV1000  Olympus (Hamburg, Germany) 
     LEO 906 E  Zeiss (Oberkochen, Germany) 
     Stemi 200 with KL 200 Zeiss (Oberkochen, Germany) 
Neurosoft-Evidence 3102 electromyograph Schreiber & Tholen Medizintechnik (Stade, 
Germany) 
Object slides superfrost  Langenbrinck (Teningen, Germany) 
Optical adhesive covers Applied Biosystems (Darmstadt, Germany) 
PapPen  SCI (Munich, Germany) 
PCR tubes  Hartenstein (Wuerzburg, Germany) 
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Perfusion pump Reglo  Ismatec (Glattbrugg, Switzerland) 
ProScan Slow Scan CCD camera  Pro Scan (Lagerlechfeld, Germany) 
Pipettes  Abimed (Berlin, Germany) 
 Eppendorf (Hamburg, Germany) 
 Gilson (Bad Camberg, Germany) 
Power supply Bio-RAD (Munich, Germany) 
PROTRAN® Nitrocellulose Transfer Hartenstein (Wuerzburg, Germany) 
Membrane 
Sonication device Sonoplus HD60  Bandelin Electronic (Berlin, Germany) 
Thermocycler  
     Step One Plus Real Time PCR System Applied Biosystems (Darmstadt, Germany) 
     Mastercycler gradient  Eppendorf (Hamburg, Germany) 
     Primus96 advanced  Peqlab (Erlangen, Germany) 
Ultracut  Leica (Wetzlar, Germany) 
 
Software 
     Adobe Photoshop CS3  Adobe (San Jose, USA) 
     Evidence Schreiber & Tholen Medizintechnik (Stade, 
Germany) 
     FluoView  Olympus (Hamburg, Germany) 
     iTEM  Olympus (Hamburg, Germany) 
     ImageJ  NIH (Bethesda, USA) 
     Office 2007  Microsoft (Redmond, USA) 
     PASW Statistics 18 SPSS  IBM (Ehningen, Germany) 
 
8.2. Reagents 
 
Acetone  Invitrogen (Karlsruhe, Germany) 
Agarose Carl Roth (Karlsruhe, Deutschland) 
-Bungarotoxin  Thermo Scientific (Darmstadt, Germany) 
Ammonium chloride  Merck (Darmstadt, Germany) 
Ammonium persulfate (APS) Carl Roth (Karlsruhe, Deutschland) 
AmpliTaq DNA Polymerase  Applied Biosystems (Darmstadt, Germany) 
Aqua-Poly/Mount
®
 Polysciences (Eppelheim, Germany) 
Avidin-Biotin blocking kit Vector Laboratories (Burlingame, USA) 
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Boric acid Merck (Darmstadt, Germany) 
Bovine serum albumine (BSA) 96% Sigma-Aldrich (Munich, Germany) 
Bromphenol blue Sigma-Aldrich (Munich, Germany) 
Chloroform  Sigma-Aldrich (Munich, Germany) 
DAPI Sigma-Aldrich (Munich, Germany) 
Diethylpyrocarbonate (DEPC) Sigma-Aldrich (Munich, Germany) 
1, 4-Dithiothreitol (DTT)  Sigma-Aldrich (Munich, Germany) 
ECL detection reagents Ge Healthcare (Munich, Germany) 
Ethylenediaminetetraacetic acid (EDTA)  Merck (Darmstadt, Germany) 
Ethanol  Sigma-Aldrich (Munich, Germany) 
Folin-Ciocalteu's phenol reagent, 2N Carl Roth (Karlsruhe, Germany) 
Gel Star DNA-Dye Lonza (Basel, Switzerland) 
Glycine  Sigma-Aldrich (Munich, Germany) 
Glycerol  Merck (Darmstadt, Germany) 
Glycogen Roche (Mannheim, Germany) 
HD Green DNA-Dye Intas (Goettingen, Germany) 
Heparin  Ratiopharm (Ulm, Germany) 
Hepes  Carl Roth (Karlsruhe, Germany) 
Ketavet Pfizer (Berlin, Germany) 
Lowry powder  Sigma-Aldrich (Munich, Germany) 
2-Mercaptoethanol Thermo Scientific (Darmstadt, Germany) 
Methanol  Sigma-Aldrich (Munich, Germany) 
2-Methylbutane  Carl Roth (Karlsruhe, Germany) 
Nonidet P-40 substitute (NP-40)  Fluka (Buchs, Swiss) 
O.C.T. medium  Sakura (Alphen aan den Rijn, Netherlands) 
O Range Ruler 600bp DNA ladder  Thermo Scientific (Darmstadt, Germany) 
Orange Loading Dye (6x)  Thermo Scientific (Darmstadt, Germany) 
Page Ruler Plus prestained protein ladder Thermo Scientific (Darmstadt, Germany) 
Primers  Sigma-Aldrich (Munich, Germany) 
Potassium di-hydrogen phosphate  Merck (Darmstadt, Germany) 
Potassium chloride  Merck (Darmstadt, Germany) 
Potassium hydrogen carbonate  Merck (Darmstadt, Germany) 
Polyacrylamid  Carl Roth (Karlsruhe, Germany) 
Ponceau S Carl Roth (Karlsruhe, Germany) 
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Roti
®
-Block (10x) Carl Roth (Karlsruhe, Germany) 
Protease inhibitor cocktail set Calbiochem (Darmstadt, Germany) 
Sodium chloride solution  Merck (Darmstadt, Germany) 
Sodium dodecyl sulfate (SDS)  Carl Roth (Karlsruhe, Germany) 
Streptavidin Biozol (Eching, Germany) 
Sucrose Carl Roth (Karlsruhe, Germany) 
Tetramethylethylenediamine (TEMED) Sigma-Aldrich (Munich, Germany) 
Tris(hydroxymethyl)aminomethane (Tris)  Merck (Darmstadt, Germany) 
Tris-HCl Merck (Darmstadt, Germany) 
TritonX-100  Carl Roth (Karlsruhe, Germany) 
Tween20  Carl Roth (Karlsruhe, Germany) 
Vinyl/ERL4221D  ServaElectrophoresis 
 (Heidelberg, Germany) 
Vitro-Clud
®
  Langenbrinck (Teningen, Germany) 
Xylavet CP-Pharma (Burgdorf, Germany) 
 
 
8.3. Buffers and solutions 
 
Anaesthetic  1.2% Ketavet 
 0.08% Xylavet 
 0.9% NaCl 
 
DABCO  25% PBS 
 75% Glycerol 
 25 mg/ml 1,4-diazabicyclo[2.2.2]octane 
 Store at 4°C protected from light 
 
DEPC-H2O 0.01% diethyl pyrocarbonate (DEPC) 
 Dissolve in distilled water, autoclave 
 
Gel running buffer (10x) 0.25M Tris 
 1.92M Glycin 
 1% SDS 
 Store at 4°C 
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Laemmli (6x) 12% Tris-HCl 
 12% SDS 
 2.4% EDTA 
 20% Glycerol 
 0.1% Bromphenol blue 
 4.75% 2-Mercaptoethanol 
 Store at -20°C 
 
Methylene blue  1% Methylene blue 
 1% Azure II 
 40% Saccharose  
 pH 9.2 
 
PBS (1x) 137 mM NaCl 
 2.7 mM KCl 
 1.5 mM KH2PO4 
 8.1 mM Na2HPO4 
 pH 7.4 
 
PBST (1x) 0.1% Tween 20 
 in PBS 
 
Ponceau S 1% Trichloroacetic acid 
 0.1% Ponceau S 
 Store protected from light 
 
RIPA lysis buffer  25 mM Tris pH 8 
 10 mM Hepes pH 4.4 
 150mM NaCl 
 5mM MgCl2 
 145 mM KCl 
 0.4 % EDTA 
 0.1 % SDS 
 1% Nonidet P40 
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 10 % Glycerol 
 Store at 4°C 
 
SDS PAGE buffer (10x)  0.25M Tris 
 1.92M Glycine 
 1% SDS  
 Store at 4°C 
 
Separating gel buffer (4x) 1.5M Tris 
 0.4% SDS  
 0.4% TEMED  
 pH 8.8 
 Store at 4°C 
 
Spurr’s medium  10 g Vinyl/ERL 
 6 g DER 736 
 26 g NSA 26g 
 0.4 g DMAE 
 
Stacking gel buffer (4x)  0.5M Tris 
 0.4% SDS 
 0.4% TEMED 
 pH 6.8 
 Store at 4°C 
 
Stripping-buffer  0.2M Glycine 
 0.1% SDS 
 20mM Dithiotreitol 
 1% Tween20 
 pH 2.1 
 Store at 4°C 
 
TBE 89mM Tris 
 89mM Borate 
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 2mM EDTA 
 pH 8.0 
 
Transfer buffer (10x) 0.25M Tris 
 1.92M Glycine 
 Store at 4°C. 
 
Transfer buffer (1x) 20% Methanol 
 Dissolve in 1x Transfer buffer 
 
Unless otherwise mentioned, distilled water was used as solvent and solutions were stored 
at room temperature. 
 
 
8.4. Primer sequences for genotyping 
 
P0 
S 1295 5’-TCAGTTCCTTGTCCCCCGCTCTC-3’ 
AS 1606 5’-GGCTGCAGGGTCGCTCGGTGTTC-3’ 
AS 1772 5’-ACTTGTCTCTTCTGGGTAATCAA-3’ 
 
JHD  
JH FW 5’-GAGGAGACGGTGACCGTGGTCCCTGC-3’ 
JH Rev 5’-GGACCAGGGGGCTCAGGTCACTC-AGG-3’ 
Neo FW 5’-GCCGCATTGCATCAGCCATGAT-GGA-3’ 
Neo Rev 5’-CCTTGCGCAGCTGTGC-TCGACGTTG-3’  
 
RAG1 
RAG-1F1 5’-GAGGTTCCGCTACGACTCTG-3’ 
RAG-1F2 5’-CCGGACAAGTTTTTCAT-CGT-3’ 
RAG-1R 5’-TGGATGTGGAATTGTTGCGAG-3’ 
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8.5. Antibodies used in immunohistochemistry 
 
Primary antibodies 
 
Reactivity Host 
Catalog 
number 
Company Dilution 
Fixation / 
Additives 
Conju-
gation 
B220 Rat 550286 BD Pharm. 1:100 Acetone / - none 
-III-Tubulin Rabbit ab18207 Abcam 1:500 - / - none 
C3 Goat 0855500 
MP 
Biomedicals 
1:100 
Acetone / 
0.3% 
TritonX 
FITC 
CD4 Rat MCA1767 Serotec 1:1000 Acetone / - none 
CD8 Rat MCA609G Serotec 1:500 Acetone / - none 
CD86 Rat 553688 BD Pharm. 1:100 Acetone / - none 
CD206 Rat MCA2235 Serotec 1:2000 
Acetone / 
0.3% 
TritonX 
none 
F4/80 Rat MCA497B Serotec 1:300 Acetone / - Biotin 
IgG-Fc Goat 
715-166-
150 
Dianova 1:300 - / - Cy3 
IgG-Fc Rabbit 31194 
Thermo 
Scientific 
1:1000 - / - none 
P0 Chicken 
NB100-
1607 
Acris 1:500 
Acetone / 
0.2% 
TritonX 
none 
SMI32 Mouse smi-32r Covance 1:10000 
Acetone / 
0.2% 
TritonX 
none 
Synaptophysin 
Guinea 
pig 
101004 
Synaptic 
Systems 
1:500 
- / 0.3% 
TritonX 
none 
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Secondary antibodies 
 
Reactivity Host Catalog number Company Dilution Conjugation 
Chicken IgG Goat A-11039 Invitrogen 1:300 AF488 
Guinea pig IgG Donkey 706-165-148 Dianova 1:300 Cy3 
Mouse IgG Goat 115-175-146 Dianova 1:500 Cy5 
Rabbit IgG Goat 111-165-144 Dianova 1:300 Cy3 
Rat IgG Goat 112-165-167 Serotec 1:300 Cy3 
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9. Abbreviations  
 
AF  Alexa fluor 
BSA Bovine serum albumine 
°C Degree Celsius 
CCL Chemokine (C-C motif) ligand 
CD Cluster of differentiation 
cDNA Complementary DNA 
CHN Congenital hypomyelinating neuropathy  
CIDP  Chronic inflammatory demyelinating    
polyneuropathy 
CMAP Compound muscle action potential  
CMT Charcot-Marie-Tooth 
CR3 (CD11b) Complement receptor 3 
CSF-1/M-CSF Macrophage colony stimulating factor 
CSF-1R CSF-1 receptor 
Cx32/Gjb1 Connexin 32 / Gap junction protein, beta-1 
Cy Cyanine 
DABCO 1,4Diazobicyclo[222]octan 
DAPI 4',6-diamidino-2-phenylindole 
DEPC Diethylpyrocarbonate 
DMAE Dimethylethanolamine 
DNA Deoxyribonucleic acid 
dNTP Deoxynucelosidtriphosphate 
DSN Dejerine-Sottas neuropathy 
DTT 1,4-Dithiothreitol  
ECL  Enhanced chemiluminescence   
EDTA Ethylene diamine tetraacetic acid 
EGR2/KROX20 Early growth response protein 2 
ERK1/2 Extracellular-signal regulated kinase  
ERL  Epoxycyclohexylmethyl-3,4-    
epoxycyclohexylcarboxylate 
FcR Fc-gamma receptor 
FIZZ1 Resistin-like molecule alpha1(Relm alpha) 
9. Abbreviations 84 
h Hour 
het Heterozygous 
HMSN Hereditary motor and sensory neuropathy 
HRP Horseradish peroxidase 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
IL Interleukin 
INF Interferon-gamma 
iNOS Inducible nitric oxide synthase 
ITAM Immunoreceptor tyrosine-based activation 
 motif 
i.v. Intravenously 
IVIG Intravenous immunoglobulin 
JHD Jh-region deficient 
kDa Kilo Dalton 
KLH Keyhole limpet hemocyanin 
LIF Leukemia inhibitory factor 
MCP-1/CCL2 Monocyte chemoattractant protein 
MFN2 Mitofusin 2 
min Minutes 
MPZ/P0 Myelin protein zero 
mRNA Messenger RNA 
MTMR2 Myotubularin-related protein 2 
MuLV Murine Leukemia Virus 
NCV Nerve conduction velocity 
NEFL Neurofilament light polypeptide 
NSA Nonenylsuccinic anhydride 
PBS / PBST Phosphate buffered saline / PBS Tween 
PCR Polymerase chain reaction 
PD-1 Programmed cell death 1 
PFA Paraformaldehyde 
PMP22 Peripheral myelin protein-22 
PNS Peripheral nervous system 
qRT-PCR Semiquantitative real-time PCR 
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RAG Recombination activating gene 
RIPA Radio-immuno precipitation assay 
rRNA Ribosomal RNA 
RNA Ribonucleic acid 
RT Room temperature 
s Seconds 
SC Schwann cell 
SD Standard deviation 
SDS Sodium dodecylsulfate 
SDS-PAGE SDS polyacrylamide gel electrophoresis 
TAM Tumor associated macrophages 
TBE Tris-borate-EDTA 
TCR- T-cell receptor alpha 
TEMED Tetramethylethylenediamine 
TGF- Transforming growth factor-beta 
TLR Toll-like receptor 
TNF Tumor necrosis factor-alpha 
TREM-2  Triggering receptor expressed on myeloid 
cells-2 
Tris Tris(hydroxymethyl)aminomethane 
UPR Unfolded protein response 
wt  Wildtype 
Ym1 Chitinase 3‑like 3 
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